JP2018064542A - Fibroin-like protein variant and cell culture method - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a scaffold for culturing cells as a technique for replacing feeder cells for culturing stem cells which can efficiently culture stem cells.SOLUTION: A fibroin-like protein variant which has been induced to have a cell adhesion sequence which does not include RGD (Arg-Gly-Asp) in a fibroin-like protein repeated structure on the basis of the discovery that stem cells can be efficiently cultured in a cell adhesion sequence which does not include the typical example of a cell adhesion sequence of RGD, a cell culture vessel coated with the protein, and a culture method of the stem cells etc. using the vessel.SELECTED DRAWING: Figure 1

Description

  The present invention relates to a modified fibroin-like protein and a cell culture method using the same.

Stem cells, especially pluripotent stem cells such as embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells) are expected to be applied to regenerative medicine. Usually, feeder cells are used for culturing stem cells. However, development of a technique for substituting feeder cells is being promoted due to limitations in clinical application.

  For example, it is known to culture stem cells using a cell adhesion protein such as fibronectin or laminin as a scaffold for cell culture. In addition, it is known that stem cells are cultured using a fibroin variant obtained by introducing a cell adhesion sequence into a spider or silkworm fibroin as a scaffold for cell culture (Patent Documents 1 and 2, Non-Patent Document 1). As the cell adhesion sequence, typically, an amino acid sequence containing RGD (Arg-Gly-Asp) is known. On the other hand, for example, in laminin, a cell adhesion sequence not containing RGD has also been found.

  However, it has not been known that a stem cell can be efficiently cultured by using a fibroin variant in which a cell adhesion sequence not containing RGD is introduced into a fibroin repetitive structure as a scaffold for cell culture.

WO2015 / 036619 Special table 2013-523174

Bini E, Foo CW, Huang J, Karageorgiou V, Kitchel B, Kaplan DL., Biomacromolecules. 2006 Nov; 7 (11): 3139-45., RGD-functionalized bioengineered spider dragline silk biomaterial.

  An object of the present invention is to provide a technique for efficiently culturing cells such as stem cells.

  As a result of intensive studies, the present inventor has found a cell adhesion sequence not containing RGD in the amino acid sequence of the cell adhesion protein, and further introduced fibroin in which a cell adhesion sequence not containing RGD is introduced into the repetitive structure of the fibroin-like protein. The present inventors have found that stem cells can be efficiently cultured by using a modified protein-like protein as a scaffold for cell culture, thereby completing the present invention.

That is, the present invention can be exemplified as follows.
[1]
A protein comprising a repetitive structure and a cell adhesion sequence,
The repeating structure consists of 3 to 15 repetitions of the repeating unit,
Each repeating unit is formed by connecting an Ala-rich part and an Ala-non-rich part,
Each Ala-rich site consists of an amino acid sequence of 8 to 54 residues,
The ratio of Ala residues in each Ala-rich site is 30% or more,
Each Ala-rich site contains at least one Ala residue in any four consecutive amino acid residues in the same site;
Each non-Ala-rich site consists of an amino acid sequence of 4 residues or more,
The ratio of Ala residues in each Ala non-rich site is 20% or less,
The cell adhesion sequence is contained in one or more repeating units selected from repeating units constituting the repeating structure;
A protein in which each cell adhesion sequence is a partial amino acid sequence of a cell adhesion protein and comprises an amino acid sequence of 5 or more residues that does not contain Arg-Gly-Asp.
[2]
The protein, wherein the cell adhesion sequence is contained in two or more repeating units selected from repeating units constituting the repeating structure.
[3]
The said protein whose total number of the said cell-adhesion arrangement | sequence contained in the said protein is 1-50.
[4]
The protein, wherein each cell adhesion sequence is inserted in an Ala non-rich site or a junction between an Ala-rich site and an Ala non-rich site.
[5]
The protein, wherein the cell adhesion protein is laminin or vitronectin.
[6]
The protein, wherein each cell adhesion sequence consists of an amino acid sequence described in the following (a), (b), or (c):
(A) amino acid sequence represented by amino acid numbers 2113 to 2124 of SEQ ID NO: 71; amino acid numbers 2866 to 2880, 2905 to 2915, 3102 to 3111, 3204 to 3209, 3260 to 3270, 3264 to 3270, 3264 to 3286 of SEQ ID NO: 6 , Or the amino acid sequence shown in 3306-3319; the amino acid sequence shown in amino acid number 1567-1581 of SEQ ID NO: 22, or the amino acid sequence shown in amino acid number 1411-1419 of SEQ ID NO: 25; ˜2216, 2397 to 2402, 2742 to 2753, or 2745 to 2752; the amino acid sequence shown to amino acid numbers 367 to 377 of SEQ ID NO: 33; the starting position of these amino acid numbers and / or Or a combination of their amino acid sequence; amino acid sequence completion position is one behind 1-5 residues;
(B) an amino acid sequence comprising 1 to 3 amino acid residue substitutions, deletions, insertions, and / or additions in the amino acid sequence shown in (a), and does not contain Arg-Gly-Asp; (c) An amino acid sequence having 80% or more identity to the amino acid sequence shown in (a) and not containing Arg-Gly-Asp.
[7]
The protein, wherein each cell adhesion sequence consists of an amino acid sequence described in the following (a), (b), or (c):
(A) the amino acid sequence shown in any one of SEQ ID NOs: 34 to 44, 47, 49, 50, and 72 to 74;
(B) including substitution, deletion, insertion, and / or addition of 1 to 3 amino acid residues in the amino acid sequence shown in any of SEQ ID NOs: 34 to 44, 47, 49, 50, and 72 to 74, And an amino acid sequence not containing Arg-Gly-Asp;
(C) an amino acid sequence having 80% or more identity to the amino acid sequence shown in any of SEQ ID NOs: 34 to 44, 47, 49, 50, and 72 to 74 and not containing Arg-Gly-Asp .
[8]
The protein, wherein each cell adhesion sequence is composed of an amino acid sequence showing a function of inhibiting adhesion of an induced pluripotent stem cell to a cell scaffold.
[9]
The protein, wherein each Ala-rich site consists of an amino acid sequence of 8 to 15 residues. [10]
The protein, wherein each Ala-rich site consists of an amino acid sequence of 9 residues.
[11]
The protein, wherein each Ala-rich site contains one or more Gly residues and Ser residues.
[12]
The said protein whose ratio of the Ala residue in each Ala rich site | part is 50% or more.
[13]
The said protein whose ratio of the Ala residue, Gly residue, and Ser residue in each Ala rich site | part is 90% or more in total.
[14]
The protein in which each Ala-rich site consists of the amino acid sequence described in the following (a), (b), or (c):
(A) the amino acid sequence shown in SEQ ID NO: 7, 8, 9, or 10;
(B) an amino acid sequence comprising substitution, deletion, insertion, and / or addition of 1 to 3 amino acid residues in the amino acid sequence shown in SEQ ID NO: 7, 8, 9, or 10;
(C) an amino acid sequence having 80% or more identity to the amino acid sequence shown in SEQ ID NO: 7, 8, 9, or 10.
[15]
The protein, wherein each Ala non-rich site consists of an amino acid sequence of 15 to 100 residues.
[16]
The said protein whose ratio of the Ala residue in each Ala non-rich site | part is 5% or less.
[17]
The said protein whose ratio of Gly residue, Ser residue, Gln residue, Pro residue, and Tyr residue in each Ala non-rich site is 90% or more in total.
[18]
The protein, wherein each Ala non-rich site comprises one or more amino acid sequences selected from the amino acid sequences described in the following (a), (b), and (c):
(A) the amino acid sequence shown in SEQ ID NOs: 11 to 21;
(B) an amino acid sequence comprising substitution, deletion, insertion and / or addition of 1 to 3 amino acid residues in the amino acid sequence shown in SEQ ID NOs: 11 to 21;
(C) An amino acid sequence having 80% or more identity to the amino acid sequences shown in SEQ ID NOs: 11 to 21.
[19]
The protein, wherein each Ala non-rich site consists of the amino acid sequence described in the following (a), (b), or (c):
(A) amino acid numbers 62-91, 101-120, 130-151, 161-185, 195-218, 228-257, 267-291, 301-325, 335-369, 379-438, 448 of SEQ ID NO: 2. The amino acid sequence shown in ~ 497 or 507-536;
(B) amino acid numbers 62-91, 101-120, 130-151, 161-185, 195-218, 228-257, 267-291, 301-325, 335 of SEQ ID NO: 2.
369, 379-438, 448-497, or 507-536, the amino acid sequence comprising 1-10 amino acid residue substitutions, deletions, insertions, and / or additions;
(C) amino acid numbers 62-91, 101-120, 130-151, 161-185, 195-218, 228-257, 267-291, 301-325, 335-369, 379-438, 448 of SEQ ID NO: 2. An amino acid sequence having 90% or more identity to the amino acid sequence shown in ˜497 or 507 to 536.
[20]
A composition comprising the protein.
[21]
The composition, which is a cell scaffold material.
[22]
The composition described above, wherein the cell scaffold material is used for culturing stem cells.
[23]
The composition, wherein the stem cell is an embryonic stem cell or an induced pluripotent stem cell.
[24]
The said composition which is a coating agent of a cell culture container.
[25]
The composition described above, wherein the cell culture container is for stem cell culture.
[26]
The composition, wherein the stem cell is an embryonic stem cell or an induced pluripotent stem cell.
[27]
An instrument comprising the protein.
[28]
Said instrument, which is a medical or research instrument.
[29]
The instrument, which is a cell culture vessel.
[30]
The device, which is a cell scaffold material.
[31]
The instrument, wherein the cell culture surface is coated with the protein.
[32]
The device for culturing stem cells.
[33]
The device, wherein the stem cell is an embryonic stem cell or an induced pluripotent stem cell.
[34]
A method for producing cultured cells, comprising culturing cells with the device.
[35]
The method, wherein the cultured cells are stem cells.
[36]
The method, wherein the stem cell is an embryonic stem cell or an induced pluripotent stem cell.
[37]
A gene encoding the protein.
[38]
A vector carrying the gene.
[39]
A host having the gene.

  According to the present invention, cells such as stem cells can be efficiently cultured.

It is a figure which shows the result of having coated a laminin partial sequence insertion fibroin-like protein on the cell culture plate, and evaluating the iPS cell scaffold function. It is a figure which shows the result of having coated the laminin partial arrangement | sequence insertion fibroin-like protein on the cell culture plate, and evaluating the iPS cell scaffold function over 2 weeks. The horizontal axis indicates “week”. It is a figure which shows the result of having evaluated the iPS cell adhesion inhibitory function of laminin partial arrangement | sequence RKRLQVQLSIRT in the cell culture plate which coated iMatrix. It is a figure which shows the result of having evaluated the iPS cell adhesion inhibitory function of laminin partial arrangement | sequence RKRLQVQLSIRT in the cell culture plate coated with Matrigel. It is a figure which shows the result of having evaluated the iPS cell adhesion inhibitory function of laminin partial arrangement | sequence GCISNVFVQRLL in the cell culture plate which coated iMatrix. It is a figure which shows the result of having evaluated the iPS cell adhesion inhibitory function of laminin partial arrangement | sequence AASIKVAVSADR in the cell culture plate which coated iMatrix. It is a figure which shows the result of having evaluated the iPS cell adhesion inhibitory function of modified laminin partial arrangement PGASIKVAVSAGPS in the cell culture plate which coated iMatrix.

  Hereinafter, the present invention will be described in detail.

<1> Protein of the Present Invention <1-1> Protein of the Present Invention The protein of the present invention is a protein comprising a repeating structure and a cell adhesion sequence.

  Specifically, the protein of the present invention may be a fibroin-like protein into which a cell adhesion sequence is inserted. That is, the protein of the present invention is also referred to as “cell adhesion sequence-inserted fibroin-like protein”.

  In the present invention, “fibroin-like protein” is a general term for fibroin and proteins having a structure equivalent thereto.

“Fibroin” is a fibrous protein that forms spider silk and silkworm silk. That is, examples of fibroin include spider fibroin and silkworm fibroin. The type of spider, silkworm, and yarn are not particularly limited. Spiders include Araneus diadematus and American spider (Nephila clavipes). Other spiders include Araneus bicentenarius, Argiope amoena, Argiope aurantia, Argiope trifasciata, Cyrtophora moluccensis, Dolomedes tenebrosus, Euprosthenops australis, Gasteracantha mammosa, Latrodectus geometricus, Latrodectus hesperus, eph, Octonoba varians, Psechrus sinensis, Tetragnatha kauaiensis, Tetragnatha versicolor. Spider fibroin is produced by bookmark thread, frame thread, warp protein (large bottle-shaped gland protein) produced by large bottle-shaped gland, scaffold thread protein (small bottle-shaped gland protein) produced by small bottle-shaped gland, and flagellate gland And weft protein (flagellate protein). Specific examples of spider fibroin include the large bottle-shaped gland proteins ADF3 and ADF4 of the spider spider and the large bottle-shaped gland proteins MaSp1 and MaSp2 of the American spider spider. The silkworms include Bombyx mori and Samia cynthia.
). The amino acid sequences of these fibroin and the base sequence of the gene encoding these fibroin (also referred to as “fibroin gene”) can be obtained from public databases such as NCBI (http://www.ncbi.nlm.nih.gov/). You can get it.

  “Protein having a structure similar to fibroin” refers to a protein having the same sequence as the repetitive sequence of fibroin. The “sequence similar to the repetitive sequence possessed by fibroin” may be a sequence actually possessed by fibroin or a sequence similar thereto. Examples of the sequence similar to the repetitive sequence possessed by fibroin include the “repeated structure” defined in the present invention. Examples of the protein having a structure similar to fibroin include a polypeptide derived from a large sphincter bookmark protein described in WO2012 / 165476 and a recombinant spider silk protein described in WO2006 / 008163. Examples of the protein having a structure similar to fibroin include ADF3 protein used in Examples. The base sequence of the ADF3 gene used in the Examples is shown in SEQ ID NO: 1, and the amino acid sequence of the ADF3 protein encoded by the same gene is shown in SEQ ID NO: 2. The base sequence from the 7th position to the 1989 position of SEQ ID NO: 1 encodes the amino acid sequence shown in SEQ ID NO: 2. The protein having a structure similar to fibroin may or may not be a fibrous protein.

  “Fibrous protein” refers to a protein that takes a fibrous form under predetermined conditions. That is, the fibrous protein may be a protein expressed in a fibrous form, or may be a protein that can be processed into a fibrous form although not in a fibrous form at the time of expression. The fibrous protein may be, for example, a protein that is expressed as an inclusion body and can then be processed into a fibrous form by an appropriate technique. As a technique for processing a protein into a fibrous form, for example, a method described in WO2012 / 165476 can be mentioned.

  That is, the fibroin-like protein may be, for example, a protein having the amino acid sequence shown in SEQ ID NO: 2 or the amino acid sequence of the fibroin-like protein disclosed in the above database or literature. The fibroin-like protein may be a protein having a part of the amino acid sequence, for example. A part of the amino acid sequence includes a part having the same sequence as the repetitive sequence of fibroin. Specific examples of the amino acid sequence include the amino acid sequence at positions 25 to 610 and the amino acid sequence at positions 53 to 536 in SEQ ID NO: 2. Similarly, a gene encoding a fibroin-like protein (also referred to as “fibroin-like protein gene”) is, for example, the base sequence of the fibroin gene disclosed in the above database or literature, or the base sequence of positions 7 to 1989 of SEQ ID NO: 1. It may be a gene having The fibroin-like protein gene may be a gene having a part of the base sequence, for example. As a part of the base sequence, a part encoding an amino acid sequence having the same sequence as the repetitive sequence possessed by fibroin can be mentioned. In addition, the expression “having an (amino acid or base) sequence” includes the case of “including the (amino acid or base) sequence” and the case of “consisting of the (amino acid or base) sequence”.

  As long as the original function is maintained, the fibroin-like protein may be a variant of the fibroin-like protein exemplified above (that is, the fibroin exemplified above or a protein having a structure equivalent thereto). Similarly, a fibroin-like protein gene is a variant of the fibroin-like protein gene exemplified above (that is, a gene encoding fibroin exemplified above or a protein having a structure equivalent thereto) as long as the original function is maintained. Also good. Such a variant in which the original function is maintained may be referred to as a “conservative variant”. Examples of the conservative variant include the above-exemplified fibroin-like protein, homologues of genes encoding the same, and artificially modified variants.

“The original function is maintained” means that the variant of the gene or protein has a function (activity or property) corresponding to the function (activity or property) of the original gene or protein. In other words, in the case of fibroin-like protein, "the original function is maintained"
It means that a protein variant exhibits a scaffold function for cells such as stem cells by inserting a cell adhesion sequence. In addition, in the case of a fibroin-like protein gene, “the original function is maintained” means that the variant of the gene is a protein in which the original function is maintained (that is, a cell such as a stem cell by insertion of a cell adhesion sequence). It encodes a protein that exhibits a scaffold function.

  Examples of homologs of fibroin-like proteins include proteins obtained from public databases by BLAST search and FASTA search using the amino acid sequence of the fibroin-like protein as a query sequence. The homologue of the fibroin-like protein gene can be obtained, for example, by PCR using, as a primer, an oligonucleotide prepared based on the base sequence of the fibroin-like protein gene using chromosomes of various organisms as templates.

  Hereinafter, conservative variants of fibroin-like protein and fibroin-like protein gene will be exemplified.

  As long as the original function of the fibroin-like protein is maintained, one or several amino acids at one or several positions are substituted, deleted, inserted, and / or added in the amino acid sequence of the fibroin-like protein. It may be a protein having an amino acid sequence. The above “one or several” varies depending on the position and type of the protein in the three-dimensional structure of the amino acid residue, and specifically, for example, 1 to 50, 1 to 40, 1 to 30, Preferably 1 to 20, more preferably 1 to 10, more preferably 1 to 5, particularly preferably 1 to 3.

One or several amino acid substitutions, deletions, insertions, and / or additions described above are conservative mutations in which the function of the protein is maintained normally. A typical conservative mutation is a conservative substitution. Conservative substitution is a polar amino acid between Phe, Trp, and Tyr when the substitution site is an aromatic amino acid, and between Leu, Ile, and Val when the substitution site is a hydrophobic amino acid. In this case, between Gln and Asn, when it is a basic amino acid, between Lys, Arg, and His, when it is an acidic amino acid, between Asp and Glu, when it is an amino acid having a hydroxyl group Is a mutation that substitutes between Ser and Thr. Specifically, substitutions considered as conservative substitutions include substitution from Ala to Ser or Thr, substitution from Arg to Gln, His or Lys, substitution from Asn to Glu, Gln, Lys, His or Asp, Asp to Asn, Glu or Gln, Cys to Ser or Ala, Gln to Asn, Glu, Lys, His, Asp or Arg, Glu to Gly, Asn, Gln
, Lys or Asp substitution, Gly to Pro substitution, His to Asn, Lys, Gln, Arg or Tyr substitution, Ile to Leu, Met, Val or Phe substitution, Leu to Ile, Met, Val Or Phe, Lys to Asn, Glu, Gln, His or Arg, Met to Ile, Leu, Val or Phe, Phe to Trp, Tyr, Met, Ile or Leu, Ser To Thr or Ala, Thr to Ser or Ala, Trp to Phe or Tyr, Tyr to His, Phe or Trp, and Val to Met, Ile or Leu Can be mentioned. In addition, substitution, deletion, insertion, and / or addition of amino acids as described above are caused by naturally occurring mutations (mutants or variants) such as cases based on individual differences or species differences of the organism from which the protein is derived. Also included.

  Further, as long as the original function is maintained, the fibroin-like protein is 80% or more, preferably 90% or more, more preferably 95% or more, more preferably 97%, based on the entire amino acid sequence of the fibroin-like protein. % Or more, particularly preferably a protein having an amino acid sequence having a homology of 99% or more. In the present specification, “homology” refers to “identity”.

In addition, as long as the original function is maintained, the fibroin-like protein can be prepared from a base sequence of the fibroin-like protein gene, for example, a complementary sequence to the whole or a part of the base sequence, under stringent conditions. It may be a protein encoded by DNA that hybridizes with Such a probe can be prepared, for example, by PCR using an oligonucleotide prepared based on the base sequence as a primer and a DNA fragment containing the base sequence as a template. “Stringent conditions” refers to conditions under which so-called specific hybrids are formed and non-specific hybrids are not formed. For example, highly homologous DNAs, for example, 80% or more, preferably 90% or more, more preferably 95% or more, further preferably 97% or more, particularly preferably 99% or more. Is hybridized and DNAs with lower homology do not hybridize with each other, or washing conditions for normal Southern hybridization, 60 ° C, 1 x SSC, 0.1
% SDS, preferably 60 ° C., 0.1 × SSC, 0.1% SDS, more preferably 68 ° C., 0.1 × SSC, 0.1%
The conditions include washing once, preferably 2-3 times at a salt concentration and temperature corresponding to SDS. For example, when a DNA fragment having a length of about 300 bp is used as the probe, hybridization washing conditions include 50 ° C., 2 × SSC, and 0.1% SDS.

  Further, the fibroin-like protein gene may be obtained by replacing an arbitrary codon with an equivalent codon. That is, the fibroin-like protein gene may be a variant of the fibroin-like protein gene exemplified above due to codon degeneracy. For example, the fibroin-like protein gene may be modified to have an optimal codon depending on the codon usage of the host to be used.

  The percentage sequence identity between two sequences can be determined, for example, using a mathematical algorithm. Non-limiting examples of such mathematical algorithms include the Myers and Miller (1988) CABIOS 4: 11-17 algorithm, the Smith et al (1981) Adv. Appl. Math. 2: 482 local homology algorithm, Needleman and Hunology alignment algorithm of Wunsch (1970) J. Mol. Biol. 48: 443-453, Pearson and Lipman (1988) Proc. Natl. Acad. Sci. 85: 2444-2448 (1993) Proc. Natl. Acad. Sci. USA 90: 5873-5877, an improved algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87: 2264 Can be mentioned.

  A program based on these mathematical algorithms can be used to perform sequence comparison (alignment) to determine sequence identity. The program can be appropriately executed by a computer. Such programs include, but are not limited to, the PC / Gene program CLUSTAL (available from Intelligents, Mountain View, Calif.), The ALIGN program (Version 2.0), and the Wisconsin Genetics Software Package, Version 8 (Genetics Computer Group (GCG), 575 Science Drive, available from Madison, Wis., USA) GAP, BESTFIT, BLAST, FASTA, and TFASTA. Alignment using these programs can be performed using initial parameters, for example. For the CLUSTAL program, Higgins et al. (1988) Gene 73: 237-244, Higgins et al. (1989) CABIOS 5: 151-153, Corpet et al. (1988) Nucleic Acids Res. 16: 10881-90, Huang et al. (1992) CABIOS 8: 155-65 and Pearson et al. (1994) Meth. Mol. Biol. 24: 307-331.

In order to obtain a nucleotide sequence having homology with the nucleotide sequence encoding the protein of interest, specifically, for example, a BLAST nucleotide search can be performed with the BLASTN program, score = 100, word length = 12. In order to obtain an amino acid sequence having homology with the protein of interest, specifically, for example, BLAST protein search, BLASTX program,
This can be done with score = 50 and word length = 3. Please refer to http://www.ncbi.nlm.nih.gov for BLAST nucleotide search and BLAST protein search. In addition, Gapped BLAST (BLAST 2.0) can be used to obtain an alignment with a gap added for the purpose of comparison. PSI-BLAST (BLAST 2.0) can also be used to perform iterative searches that detect distant relationships between sequences. For Gapped BLAST and PSI-BLAST, see Altschul et al. (1997) Nucleic Acids Res. 25: 3389. When utilizing BLAST, Gapped BLAST, or PSI-BLAST, for example, the initial parameters of each program (eg, BLASTN for nucleotide sequences, BLASTX for amino acid sequences) can be used. The alignment may be performed manually.

  Sequence identity between two sequences is calculated as the percentage of residues that match between the two sequences when the two sequences are aligned for maximum matching.

  The protein of the present invention may be a protein having the same amino acid sequence as the fibroin-like protein exemplified above or a conservative variant thereof except that it contains a cell adhesion sequence. Further, the gene encoding the protein of the present invention may be a gene having the same base sequence as the fibroin-like protein gene exemplified above or a conservative variant thereof except that it includes a base sequence encoding a cell adhesion sequence. .

  Specific examples of the protein of the present invention include the cell adhesion sequence-inserted fibroin-like protein used in the examples. The nucleotide sequence of the gene encoding the cell adhesion sequence-inserted fibroin-like protein used in the Examples is shown in SEQ ID NOs: 3 and 51 to 60, and the amino acid sequence of the cell adhesion sequence-inserted fibroin-like protein encoded by the same gene is shown in SEQ ID NOs: 4 and 61. -70. That is, the protein of the present invention may be, for example, a protein having the amino acid sequence shown in any of SEQ ID NOs: 4 and 61 to 70. The protein of the present invention also specifically includes a conservative variant of the cell-insertion sequence-inserted fibroin-like protein used in the Examples and having a cell-adhesion sequence. Regarding the conservative variant of the cell adhesion sequence-inserted fibroin-like protein, the description of the conservative variant of the fibroin-like protein can be applied mutatis mutandis. “The original function is maintained” for a cell adhesion sequence-inserted fibroin-like protein means that the variant of the protein exhibits a scaffold function for cells such as stem cells.

  In the present invention, the term “gene” is not limited to DNA as long as it encodes a target protein, and may include any polynucleotide. That is, the “gene encoding the protein of the present invention” may mean any polynucleotide encoding the protein of the present invention. The gene encoding the protein of the present invention may be DNA, RNA, or a combination thereof. The gene encoding the protein of the present invention may be single-stranded or double-stranded. The gene encoding the protein of the present invention may be single-stranded DNA or single-stranded RNA. The gene encoding the protein of the present invention may be double-stranded DNA, double-stranded RNA, or a hybrid strand composed of a DNA strand and an RNA strand. The gene encoding the protein of the present invention may contain both DNA and RNA residues in a single polynucleotide chain. When the gene encoding the protein of the present invention contains RNA, the description regarding DNA such as the exemplified base sequence may be appropriately read according to RNA. The mode of the gene encoding the protein of the present invention can be appropriately selected according to various conditions such as its usage mode.

  Hereinafter, the structure of the protein of the present invention will be specifically described.

The protein of the present invention includes a repeating structure and a cell adhesion sequence. The repeating structure is composed of repeating repeating units. Each repeating unit is formed by connecting an Ala-rich part and an Ala-non-rich part. In each repeating unit, the Ala-rich part is the N-terminal side, and the Ala non-rich part is the C-terminal side. That is, specifically, the repeating structure is formed by alternately connecting Ala-rich sites and Ala-non-rich sites from the N-terminus to the C-terminus.

  The number of repeating units is 3 to 15 times. The number of repeating units may be, for example, 4 times or more, 5 times or more, 6 times or more, 7 times or more, 8 times or more, 9 times or more, or 10 times or more. The number of repeating units may be, for example, 12 times or less, 10 times or less, 8 times or less, or 6 times or less. The number of repeating units may be, for example, a consistent range of the above exemplified ranges. Specifically, the number of repeating units is, for example, 3-12 times, 3-10 times, 3-8 times, 3-6 times, 5-15 times, 7-15 times, Alternatively, it may be 10 to 15 times.

  The constitution of the repeating unit may or may not be the same in each repetition. That is, the configuration of the Ala-rich part may or may not be the same in each repetition. Further, the configuration of the Ala non-rich portion may or may not be the same in each repetition. That is, the structure of the repeating unit, the structure of the Ala-rich part, and the structure of the Ala non-rich part can be set independently in each repetition. That is, as the repeating unit, the Ala-rich site, and the Ala non-rich site, one amino acid sequence may be used, or two or more amino acid sequences may be used in combination.

<Ala-rich site>
“Ala-rich part” refers to a part having a high ratio of Ala residues (a part containing Ala residues at a high ratio).

  The length of the Ala-rich site is 8 to 54 residues. That is, the Ala-rich site consists of an amino acid sequence of 8 to 54 residues. The length of the Ala-rich site may be, for example, 40 residues or less, 30 residues or less, 20 residues or less, 15 residues or less, or 10 residues or less. The length of the Ala-rich region may be, for example, a combination range of the above-exemplified ranges. Specifically, the length of the Ala-rich site may be, for example, 8 to 15 residues, or 8 to 10 residues. More specifically, the length of the Ala-rich site may be 9 residues, for example.

  The Ala-rich site may be composed of an Ala residue, or may be composed of a combination of an Ala residue and another amino acid residue (amino acid residue other than an Ala residue).

  The ratio of Ala residues in the Ala-rich site is 30% or more. The ratio of Ala residues in the Ala-rich site may be, for example, 40% or more, 50% or more, 60% or more, or 70% or more. The ratio of Ala residues in the Ala-rich site may be, for example, 100% or less, 95% or less, 90% or less, 85% or less, or 80% or less. The ratio of Ala residues in the Ala-rich site may be, for example, a combination range of the above-exemplified ranges. Specifically, the ratio of Ala residues in the Ala-rich site may be, for example, 30% to 100%, 50% to 90%, or 60% to 85%. The “ratio of Ala residues in the Ala-rich site” is the ratio of the number of Ala residues contained in the Ala-rich site to the total number of amino acid residues constituting the Ala-rich site. The ratio of any other amino acid residue in the Ala-rich site can be calculated in the same manner.

Other amino acid residues (amino acid residues other than Ala residues) include Gly, Val, Leu, Ile, Ser, Thr, Cys, Met, Asn, Gln, Pro, Asp, Glu, Lys, Arg, His, Phe, Tyr, Trp are mentioned. Specific examples of other amino acid residues include a Gly residue and a Ser residue. The Ala-rich site may contain only one type of other amino acid residue, or may contain two or more types. The Ala-rich site may contain, for example, one or more Gly residues, may contain one or more Ser residues, and may contain one or more Gly residues and one or more Ser residues, respectively. . Both ends (N-terminal and C-terminal) of the Ala-rich site may be, for example, an Ala residue, a Gly residue, or a Ser residue, respectively. Specifically, for example, the N-terminus of the Ala-rich site may be an Ala residue or Gly residue, and the C-terminus of the Ala-rich site may be an Ala residue or Ser residue. The ratio of Ala, Gly, and Ser residues in the Ala-rich site is, for example, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 95% or more, or It may be 100%.

  The Ala-rich site contains at least one Ala residue in any consecutive 4 amino acid residues in the same site. That is, there are no consecutive 4 amino acid residues that do not contain an Ala residue in the Ala-rich site. In addition, the Ala-rich site may include at least two Ala residues in any continuous 7, 6, or 5 amino acid residues in the same site. That is, the Ala-rich site may not contain 7, 6 or 5 amino acid residues which do not contain an Ala residue or contain only one Ala residue.

  Examples of the amino acid sequence of the Ala-rich site include an amino acid sequence of a portion that satisfies the requirements for the Ala-rich site as described above in the amino acid sequence of the fibroin-like protein. The fibroin-like protein is as described above. Of the amino acid sequence shown in SEQ ID NO: 2, the portions satisfying the requirements for the Ala-rich site as described above include amino acid numbers 53 to 61, 92 to 100, 121 to 129, 152 to 160, 186 to 194, and 219 to 227. 258-266, 292-300, 326-334, 370-378, 439-447, 498-506. Specific examples of amino acid sequences that satisfy the requirements for these Ala-rich sites include GASAAAAAA (SEQ ID NO: 7), GSAAAAAAA (SEQ ID NO: 8), GASAASAAS (SEQ ID NO: 9), and GASAAAGAA (SEQ ID NO: 10). It is done. That is, the Ala-rich portion may have, for example, an amino acid sequence (for example, SEQ ID NO: 7, 8, 9, or 10) that satisfies the requirements for these Ala-rich portions.

  Moreover, the variant of the amino acid sequence (for example, sequence number 7, 8, 9, or 10) of the part which satisfy | fills the requirements of these Ala rich sites may be sufficient as an Ala rich site | part. The description of the conservative variant of the fibroin-like protein can be applied mutatis mutandis for those variants that satisfy the requirements for these Ala-rich sites. An Ala-rich site is, for example, one or several amino acids at one or several positions in an amino acid sequence (for example, SEQ ID NO: 7, 8, 9, or 10) that satisfies the requirements of these Ala-rich sites. It may have an amino acid sequence that is substituted, deleted, inserted, and / or added. In addition, although it depends on the length etc. of the part which satisfy | fills the requirements of those Ala rich parts, the above "1 or several" is, for example, 1-5 pieces, 1-4 pieces, 1-3 pieces, 1-2 pieces 1 may be sufficient. Further, the Ala-rich site is, for example, 80% or more, preferably 90% or more, based on the entire amino acid sequence (for example, SEQ ID NO: 7, 8, 9, or 10) that satisfies the requirements of these Ala-rich sites. More preferably, it may have an amino acid sequence having an identity of 95% or more, more preferably 97% or more, and particularly preferably 99% or more. There are no particular restrictions on the variants that satisfy the requirements for these Ala-rich sites as long as the modified amino acid sequence satisfies the requirements for the Ala-rich sites as described above.

<Ala non-rich site>
The “Ala non-rich site” refers to a site where the ratio of Ala residues is low.

  The length of the Ala non-rich site is 4 residues or more. That is, the Ala non-rich site consists of an amino acid sequence of 4 residues or more. The length of the Ala non-rich site may be, for example, 10 residues or more, 15 residues or more, 20 residues or more, 30 residues or more, 40 residues or more, or 50 residues or more. The length of the Ala non-rich site may be, for example, 200 residues or less, 150 residues or less, 100 residues or less, 80 residues or less, 60 residues or less, or 40 residues or less. The length of the Ala non-rich part may be a range of the above-mentioned consistent combinations. Specifically, the length of the Ala non-rich site may be, for example, 4 to 200 residues, 10 to 150 residues, or 15 to 100 residues.

  The Ala non-rich site may or may not contain an Ala residue. The ratio of Ala residues in the Ala non-rich site is 20% or less. The ratio of Ala residues in the Ala non-rich site may be, for example, 16% or less, 14% or less, 10% or less, 5% or less, or 0%.

  Specifically, the Ala non-rich site may include one or more, for example, all amino acid residues selected from, for example, Gly, Ser, Gln, Pro, and Tyr. The total ratio of Gly, Ser, Gln, Pro, and Tyr in the Ala non-rich region is, for example, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 95% or more, or 100%. It may be. The Ala non-rich site may contain 4 consecutive amino acid residues that do not contain Ala residues. The Ala non-rich site may contain, for example, consecutive 4 amino acid residues not containing Ala residues at both ends (N-terminal and C-terminal).

As an amino acid sequence of an Ala non-rich site, for example, an amino acid sequence of a portion that satisfies the requirements for an Ala non-rich site as described above in the amino acid sequence of a fibroin-like protein can be mentioned. The fibroin-like protein is as described above. Of the amino acid sequence shown in SEQ ID NO: 2, the portions satisfying the requirements for the Ala non-rich site as described above include amino acid numbers 62-91, 101-120, 130-151, 161-185, 195-218, 228- 257, 267-291, 301-325, 335-369, 379-438, 448-497, 507-536 are mentioned. That is, the Ala non-rich portion may have, for example, an amino acid sequence of a portion that satisfies the requirements for these Ala non-rich portions. In addition, specific examples of motifs included in a portion that satisfies the requirements for these Ala non-rich sites include, for example, GGYGPGSGQQG (SEQ ID NO: 11), GGNGPGSGQQG (SEQ ID NO: 12), GGYGPGYGQQG (SEQ ID NO: 13), GGYGPGSGQG (SEQ ID NO: 13). 14), PGQQG (SEQ ID NO: 15), AGQQG (SEQ ID NO: 16), SGQQG (SEQ ID NO: 17), PSQQG (SEQ ID NO: 18)
), PGGQG (SEQ ID NO: 19), PYGP (SEQ ID NO: 20), AYGP (SEQ ID NO: 21). The motifs shown in SEQ ID NOs: 11 to 14 are collectively called “motif A”, the motifs shown in SEQ ID NOs: 15 to 19 are collectively called “motif B”, and the motifs shown in SEQ ID NOs: 20 to 21 are collectively called “motif C”. Also called. That is, the Ala non-rich site may more generally have, for example, one or more selected from these motifs. Specifically, the Ala non-rich site may have, for example, motifs A and B, and may further have a motif C. When the Ala non-rich site has two or more motifs selected from these motifs, their order is not particularly limited. The Ala non-rich site may have, for example, motifs A and B from the N-terminus to the C-terminus, or may have motifs A, B, and C. The Ala non-rich site may have only one of these motifs, or may have two or more. If the Ala non-rich site has two or more of any motif, the motifs may or may not be tandem in the Ala non-rich site. The Ala non-rich site may have, for example, only one motif B or two or more. The number of motifs B contained in one Ala non-rich site may be, for example, 1 or more, 2 or more, 3 or more, 5 or more, or 7 or more,
It may be 15 or less, 10 or less, 7 or less, or 5 or less, or a combination that is consistent.

  The Ala non-rich site may be a variant of the amino acid sequence of a portion that satisfies the requirements of the Ala non-rich site or a variant of the motif included in them. The description of the conservative variant of the fibroin-like protein can be applied mutatis mutandis for the variant of the amino acid sequence of the portion satisfying the requirement of the Ala non-rich site and the variant of the motif contained therein. Ala non-rich sites are, for example, substitutions, deletions, or insertions of one or several amino acids at one or several positions in the amino acid sequences of the portions that satisfy the requirements of these Ala non-rich sites or the motifs contained in them. And / or having an added amino acid sequence. In addition, although it depends on the length etc. of the part which satisfy | fills the requirements of those Ala non-rich parts, the above "1 or several" is, for example, 1-20 pieces, 1-15 pieces, 1-10 pieces, 1-5 It may be one, one to four, one to three, one to two, or one. The Ala non-rich site is, for example, 80% or more, preferably 90% or more, more preferably 95%, with respect to the entire amino acid sequence of the portion that satisfies the requirements of the Ala non-rich site or the entire motif contained therein. More preferably, it may have an amino acid sequence having an identity of 97% or more, particularly preferably 99% or more. There are no particular limitations on the amino acid sequence variants of the portions that satisfy the requirements for these Ala non-rich sites and the motif variants contained therein, as long as the modified amino acid sequence satisfies the requirements for the Ala non-rich sites as described above.

<Cell adhesion sequence>
“Cell adhesion sequence” means an amino acid sequence capable of imparting a scaffold function for cells such as stem cells to proteins such as fibroin-like proteins. The “cell adhesion sequence” specifically refers to an amino acid sequence that can impart a scaffold function to cells such as stem cells by inserting the protein into a protein such as a fibroin-like protein. Such a property (that is, a property capable of imparting a scaffold function for a cell such as a stem cell to a protein such as a fibroin-like protein) is also referred to as “a property as a cell adhesion sequence”.

The cell adhesion sequence consists of an amino acid sequence of 5 residues or more that does not contain RGD (Arg-Gly-Asp). That is, the length of the cell adhesion sequence is 5 residues or more. The length of the cell adhesion sequence may be, for example, 50 residues or less, 30 residues or less, or 18 residues or less. The length of the cell adhesion sequence may be in the above-mentioned consistent range. Specifically, the length of the cell adhesion sequence may be, for example, 5 to 50 residues, 5 to 30 residues, or 5 to 18 residues. Examples of the cell adhesion sequence include a partial amino acid sequence of a cell adhesion protein (a part of the amino acid sequence of the cell adhesion protein) that does not contain RGD (a non-RGD sequence of the cell adhesion protein). Specific examples of the cell adhesion protein include fibronectin, vitronectin, collagen, osteopontin, and laminin. Examples of cell adhesion proteins include laminin and vitronectin. More particularly, examples of the cell adhesion protein include laminin. Laminin has a heterotrimeric structure consisting of an α chain, a β chain, and a γ chain. As subunit chains of laminins of mammals such as humans and mice, there are five types of α chains (α1 to α5), three types of β chains (β1 to β3), and three types of γ chains (γ1 to γ3). . Laminin forms various isoforms by combining these subunit chains. Specific examples of human laminin include human laminin 511 composed of α5β1γ1, human laminin 521 composed of α5β2γ1, and human laminin 332 composed of α3β3γ2. Human laminin α1 chain (NP_005550), human laminin α3 chain (NP_937762), human laminin α5 chain (NP_005551)
), Human laminin β1 chain (NP_002282), human laminin β2 chain (NP_002283), human laminin β3 chain (NP_000219), human laminin γ1 chain (NP_002284), and human laminin γ2 chain (NP_005553) are represented by SEQ ID NOs: 71, 5, 6, It shows to 22-26, respectively.
Specific examples of human laminin include human laminin 511-E8. Human laminin 511-E8 is a partial fragment of human laminin 511 and has a heterotrimeric structure consisting of an α5-E8 fragment, a β1-E8 fragment, and a γ1-E8 fragment. The α5-E8 fragment corresponds to amino acid numbers 2534-3327 of SEQ ID NO: 6. The β1-E8 fragment corresponds to amino acid numbers 1561 to 1786 of SEQ ID NO: 22. The γ1-E8 fragment corresponds to amino acid numbers 1364-1609 of SEQ ID NO: 25. In addition, mouse laminin α1 chain (NP_032506), mouse laminin α2 chain (NP_032507), mouse laminin α3 chain (NP_034810), mouse laminin α5 chain (NP_001074640), mouse laminin β1 chain (NP_032508), mouse laminin β3 chain (NP_032510) The amino acid sequences are shown in SEQ ID NOs: 27 to 32, respectively. Vitronectin includes human vitronectin. The amino acid sequence of human vitronectin is shown in SEQ ID NO: 33. The cell adhesion sequence may have an amino acid sequence of any part of these cell adhesion proteins as long as it does not contain RGD and has properties as a cell adhesion sequence.

Examples of the non-RGD sequence of the cell adhesion protein include a heparin binding sequence and an anti-integrin antibody inhibitory sequence. Specifically, as the non-RGD sequence of the cell adhesion protein, the amino acid sequence of amino acid 2113 to 2124 in the amino acid sequence of human laminin α1 chain shown in SEQ ID NO: 71; the amino acid sequence of human laminin α5 chain shown in SEQ ID NO: 6 , Amino acid numbers 2866-2880, 2905-2915, 3102-3111, 3204-3209, 3260-3270, 3264-3270, 3276-3286, 3306-3319; within the amino acid sequence of human laminin β1 chain shown in SEQ ID NO: 22 , Amino acid numbers 1567 to 1581, 1736 to 1744; amino acid sequences of human laminin γ1 chain shown in SEQ ID NO: 25, amino acid numbers 1411 to 1419; amino acid sequence of mouse laminin α1 chain shown in SEQ ID NO: 28, Amino acid number 2210-2 216, 2397 to 2402, 2742 to 2753, 2745 to 2752; among amino acid sequences of human vitronectin shown in SEQ ID NO: 33, the amino acid numbers 367 to 377 are included. Specific examples of the non-RGD sequences of these cell adhesion proteins include, for example, AASIKVAVSADR (SEQ ID NO: 73), LLNLRPDDFVFYVGG (SEQ ID NO: 34), LNEEVVSLYNF (SEQ ID NO: 35), LKRLNTTGV (SEQ ID NO: 36), VAFYSN (SEQ ID NO: 36). 37), GCISNVFVQRLL (SEQ ID NO: 72), NVFVQRL (SEQ ID NO: 38), VFDLQQNLGSV (SEQ ID NO: 39), RGLQATARKASRRS (SEQ ID NO: 4)
0), DIARAEMLLEEAKRA (SEQ ID NO: 41), KLQLLKDLE (SEQ ID NO: 42), ALGSAAADA (SEQ ID NO: 43), SIYITRF (SEQ ID NO: 44), IAFQRN (SEQ ID NO: 45), LQVQLSIR (SEQ ID NO: 46), RKRLQVQLSIRT (SEQ ID NO: 47) ), KKQRFRHRNRK (SEQ ID NO: 48). That is, the cell adhesion sequence may have, for example, a non-RGD sequence (for example, any one of SEQ ID NOs: 34 to 48, 72, and 73) of these cell adhesion proteins.

  Moreover, the start position and / or end position of the amino acid number of the non-RGD sequence of the cell adhesion protein exemplified above may be around 1 or several residues. That is, the cell adhesion sequence may have, for example, an amino acid sequence in which the start position and / or the end position of the amino acid numbers of the non-RGD sequences of these cell adhesion proteins are around one or several residues. “One or several residues” may be, for example, 1 to 5 residues, 1 to 4 residues, 1 to 3 residues, 1 to 2 residues, or 1 residue. For example, “the amino acid sequence in which the start position and / or the end position of amino acid numbers 2866 to 2880 of the amino acid sequence shown in SEQ ID NO: 6 are about N residues” (N is a positive integer) means “SEQ ID NO: 6”. The amino acid sequence shown in amino acid numbers 2866 ± N to 2880, 2866 to 2880 ± N, or 2866 ± N to 2880 ± N of the amino acid sequence shown in FIG. The same applies to other amino acid sequences and other amino acid numbers.

Further, the cell adhesion sequence may be a combination of the cell adhesion sequences exemplified above. That is, the cell adhesion sequence may be a combination of two or more selected from the cell adhesion sequences exemplified above. The term “amino acid sequence of cell adhesive protein” (for example, “partial amino acid sequence of cell adhesive protein” or “non-RGD sequence of cell adhesive protein”) includes a combination of amino acid sequences of cell adhesive protein. Are also included. Specific examples of the combination include LQVQLSIRIAFQRN (SEQ ID NO: 49).

The cell adhesion sequence may be a variant of those amino acid sequences (for example, partial amino acid sequences of cell adhesion proteins such as SEQ ID NOs: 34 to 49, 72, 73, or combinations thereof) as long as RGD is not included. . The term “amino acid sequence of cell adhesive protein” (for example, “partial amino acid sequence of cell adhesive protein” or “non-RGD sequence of cell adhesive protein”) actually includes natural cell adhesive protein. It is not limited to the amino acid sequence to be found, and variants thereof are also included. Regarding the variants of these amino acid sequences, the description of the conservative variant of the fibroin-like protein can be applied correspondingly. Cell adhesion sequences are, for example, in one or several positions other than RGD in their amino acid sequences (for example, partial amino acid sequences of cell adhesion proteins such as SEQ ID NOs: 34 to 49, 72, 73, or combinations thereof). It may have an amino acid sequence in which one or several amino acids are substituted, deleted, inserted, and / or added and does not contain RGD. In addition, although it depends on the length etc. of the part which satisfy | fills the requirements of these cell adhesion arrangement | sequences, said "1 or several" is, for example, 1-5 pieces, 1-4 pieces, 1-3 pieces, 1-2 pieces Or one. In addition, the cell adhesion sequence is, for example, the entire amino acid sequence (for example, partial amino acid sequences of cell adhesion proteins such as SEQ ID NOs: 34 to 49, 72, 73, or combinations thereof) that satisfy the requirements for the cell adhesion sequences On the other hand, having an amino acid sequence having 80% or more, preferably 90% or more, more preferably 95% or more, still more preferably 97% or more, particularly preferably 99% or more, and does not contain RGD It may be. As long as these amino acid sequence variants do not include RGD and the variant has the property of a cell adhesion sequence (the variant can impart a scaffold function to cells such as stem cells to proteins such as fibroin-like proteins) There is no particular limitation. Specific examples of variants include GKKQRFRHRNRKG (SEQ ID NO: 50) obtained by adding G to both ends of KKQRFRHRNRK (SEQ ID NO: 48) and PGASIKVAVSAGPS (SEQ ID NO: 74) which is a variant of a partial sequence of human laminin α1. . The cell adhesion sequence may also be a further variant of the amino acid sequence shown in SEQ ID NO: 50 or 74.

  That is, the cell adhesion sequence may be, for example, one having the amino acid sequence shown in any of SEQ ID NOs: 34 to 50 and 72 to 74, or a variant thereof. The cell adhesion sequence may be, for example, one having an amino acid sequence shown in any of SEQ ID NOs: 34 to 44, 47, 49, 50, and 72 to 74, or a variant thereof.

  Whether or not a certain amino acid sequence has a property as a cell adhesion sequence is confirmed by, for example, confirming whether or not the fibroin-like protein into which the amino acid sequence is inserted exhibits a scaffold function for cells such as stem cells. can do. Whether or not the protein exhibits a scaffold function for cells such as stem cells can be confirmed, for example, by culturing cells such as stem cells using a culture vessel in which the cell culture surface is coated with the protein. That is, when the proliferation of cells such as stem cells is improved by coating the cell culture surface with the protein, it can be determined that the protein exhibits a scaffold function for cells such as stem cells.

Whether or not an amino acid sequence has a property as a cell adhesion sequence is, for example, whether the amino acid sequence exhibits a function of inhibiting adhesion of cells such as stem cells to a cell scaffold (cell adhesion inhibition function). It can be confirmed by confirming whether or not. That is, when the amino acid sequence has a property as a cell adhesion sequence, when a peptide having the amino acid sequence coexists with a cell, the scaffold recognition site on the cell surface is masked by the peptide, and thus the cell scaffold material of the cell. It is thought that the adhesion to is inhibited. Whether or not the amino acid sequence exhibits a cell adhesion inhibiting function is determined by, for example, culturing cells on a cell culture plate coated with a cell scaffold in the presence or absence of a peptide having the amino acid sequence, Can be confirmed by comparing. That is, when a decrease in the number of living cells due to the peptide is observed, it can be determined that the amino acid sequence exhibits a cell adhesion inhibitory function. As the cells, for example, artificial pluripotent stem cells (iPS cells) such as 201B7 strain can be used.
As the cell scaffold, for example, a cell adhesion protein such as laminin or a material containing the same can be used. Specific examples of such a cell scaffold include iMatrix (Nippi) and Matrigel (Nippon Becton Dickinson). More specifically, the cell adhesion inhibitory function can be evaluated under the conditions described in the examples. That is, the cell adhesion sequence may have, for example, an amino acid sequence that exhibits a cell adhesion inhibitory function. Specifically, the cell adhesion sequence may have, for example, an amino acid sequence showing a function of inhibiting adhesion of iPS cells to a cell scaffold. More specifically, the cell adhesion sequence may have, for example, an amino acid sequence that exhibits a function of inhibiting adhesion of iPS cells to laminin.

  In other words, the cell adhesion sequence can be screened using the cell adhesion inhibitory function as an index. Specifically, for example, a cell adhesion sequence can be screened by evaluating a cell adhesion inhibitory function for a peptide library containing a partial amino acid sequence of a cell adhesion protein or a variant thereof. That is, the cell adhesion sequence may have an amino acid sequence screened using, for example, a cell adhesion inhibitory function as an index.

  The protein of the present invention contains a cell adhesion sequence in a repeating structure. That is, the cell adhesion sequence is inserted into the repeated structure. In other words, the repeating structure of the protein of the present invention is a repeating structure in which a cell adhesion sequence is inserted. Specifically, the cell adhesion sequence is inserted (included) in one or more repeating units selected from repeating units constituting the repeating structure. The cell adhesion sequence is inserted into, for example, two or more, three or more, four or more, five or more, six or more, or seven or more repeating units selected from repeating units constituting the repeating structure. (Included). The cell adhesion sequence may be inserted (included) in all the repeating units constituting the repeating structure, for example. One repeating unit may have only one cell adhesion sequence, or may have two or more. When one repeating unit has two or more cell adhesion sequences, the cell adhesion sequences may or may not be arranged in tandem in the repeating unit. The number of cell adhesion sequences contained in one repeating unit may be, for example, 1 or more, 2 or more, or 3 or more, or 5 or less, 3 or less, or 2 or less. Of course, they may be a consistent combination. Specifically, the number of cell adhesion sequences included in one repeating unit may be, for example, 1 to 3. The total number of cell adhesion sequences contained in the protein of the present invention may be, for example, 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, or 7 or more, It may be 50 or less, 40 or less, 30 or less, 25 or less, 20 or less, 15 or less, or 10 or less, or a combination thereof. Specifically, the total number of cell adhesion sequences included in the repeating structure may be, for example, 1 to 50, 3 to 30, or 5 to 15. When the protein of the present invention contains two or more cell adhesion sequences, the configuration of the cell adhesion sequences can be set independently. That is, as the cell adhesion sequence, one type of cell adhesion sequence may be used, or two or more types of cell adhesion sequences may be used in combination.

The position of the cell adhesion sequence in the repeating unit is not particularly limited. Each cell adhesion sequence may be inserted, for example, in an Ala non-rich site, or at a connection portion between an Ala-rich site and the Ala non-rich site. Examples of the Ala non-rich site into which the cell adhesion sequence is inserted include, for example, amino acid numbers 62 to 91, 101 to 120, 130 to 151, 161 to 185, 195 to 218, and 228 to the amino acid sequence shown in SEQ ID NO: 2. 257, 267-291, 301-325, 335-369, 379-438, 448-497, 507-536 are mentioned. More specifically, as an Ala non-rich site into which a cell adhesion sequence is inserted, for example, among amino acid sequences shown in SEQ ID NO: 2, amino acid numbers 109 and 110, 170 and 171, 203 and 204, 276 and 277, 310 And 311, 403 and 404, and 472 and 473. Examples of the linking portion between the Ala-rich portion and the non-Ala-rich portion into which the cell adhesion sequence is inserted include, for example, amino acid numbers 61 and 62, 91 and 92, 100 and 101, 120 and 121 in the amino acid sequence shown in SEQ ID NO: 2. 129 and 130, 151 and 152, 160 and 161, 185 and 186, 194 and 195, 218 and 219, 227 and 228, 257 and 258, 266 and 267, 291 and 292, 300 and 301, 325 and 326, 334 And 335, 369 and 370, 378 and 379, 438 and 439, 447 and 448, 497 and 498, and 506 and 507. In addition to being inserted into the Ala non-rich site and / or the junction between the Ala-rich site and the Ala non-rich site, the cell adhesion sequence may be inserted into another site. Examples of other parts include an Ala-rich part and an N-terminal region and a C-terminal region described later.

<Other parts>
The protein of the present invention may further contain an N-terminal region before the first repeating unit, that is, before the repeating structure. The amino acid sequence of the N-terminal region is not particularly limited. The length of the N-terminal region may be, for example, 1 residue or more, 3 residues or more, 5 residues or more, 10 residues or more, 30 residues or more, 50 residues or more, or 100 residues or more 200 residues or less, 150 residues or less, 100 residues or less, 80 residues or less, 60 residues or less, or 40 residues or less, or a consistent combination thereof. Specifically, the N-terminal region may be, for example, 1 to 200 residues. The N-terminal region may include, for example, an amino acid sequence that satisfies the requirements for an Ala non-rich site.

The protein of the present invention may further contain a C-terminal region after the last repeating unit, that is, after the repeating structure. The amino acid sequence in the C-terminal region is not particularly limited. The length of the C-terminal region may be, for example, 1 residue or more, 3 residues or more, 5 residues or more, 10 residues or more, 30 residues or more, 50 residues or more, or 100 residues or more. 200 residues or less, 150 residues or less, 100 residues or less, 80 residues or less, 60 residues or less, or 40 residues or less, or a consistent combination thereof. Specifically, the C-terminal region may be, for example, 1 to 200 residues. The C-terminal region may include, for example, an amino acid sequence that satisfies the requirements for an Ala-rich site. The C-terminal region may include, for example, an amino acid sequence having 90% or more homology with the amino acid sequence near the C-terminus of spider fibroin. Examples of the amino acid sequence near the C-terminal of spider fibroin include, for example, the amino acid sequence of C-terminal 50 residues of spider fibroin, the amino acid sequence obtained by removing C-terminal 20 residues from C-terminal 50 residues, C-terminal 50 residues An amino acid sequence obtained by removing 29 residues from the C-terminal. Specific examples of amino acid sequences near the C-terminal of spider fibroin include, for example, positions 587 to 636 (C-terminal 50) of ADF3 (partial; NCBI AAC47010.1 GI: 1263287)
Residue) amino acid sequence, amino acid sequence at positions 587 to 616, and amino acid sequence at positions 587 to 607. Specific examples of the protein of the present invention having the amino acid sequence of positions 587 to 636 of ADF3 (partial; NCBI AAC47010.1 GI: 1263287) of the spider spider at the C-terminus include, for example, any of SEQ ID NOs: 4 and 61 to 70 And a protein having the amino acid sequence shown above.

In addition, both the N-terminal region and the C-terminal region may include a functional sequence such as a peptide tag or a protease recognition sequence. As the functional sequence, one type of functional sequence may be used, or two or more types of functional sequences may be used in combination. Specific peptide tags include His tags, FLAG tags, GST tags, Myc tags, MBP (maltose binding protein), CBP (cellulose binding protein), TRX (thioredoxin), GFP (green fluorescent protein), HRP (horseradish) peroxidase), ALP (alkaline phosphatase),
Examples include the Fc region of an antibody. The peptide tag can be used, for example, for detection and purification of the expressed protein. Specific examples of the protease recognition sequence include HRV3C protease recognition sequence, Factor Xa protease recognition sequence, and proTEV protease recognition sequence. Protease recognition sequences can be used, for example, to cleave the expressed protein. His at the N-terminus
Specific examples of the protein of the present invention having a tag and an HRV3C protease recognition sequence include, for example, a protein having an amino acid sequence represented by any of SEQ ID NOs: 4 and 61 to 70.

<1-2> Production of the protein of the present invention The protein of the present invention can be produced by expressing a gene encoding the protein of the present invention in a host having the gene encoding the protein of the present invention. “Having a gene encoding the protein of the present invention” is also referred to as “having the protein of the present invention”. That is, for example, a host having a gene encoding the protein of the present invention is also referred to as a “host having the protein of the present invention”. The expression of the gene encoding the protein of the present invention is also referred to as “expression of the protein of the present invention”. The protein of the present invention can also be produced by expressing a gene encoding the protein of the present invention in a cell-free protein synthesis system.

  A host having a gene encoding the protein of the present invention can be obtained by introducing a gene encoding the protein of the present invention into an appropriate host.

The host into which the gene encoding the protein of the present invention is introduced is not particularly limited as long as it can express the protein of the present invention. Examples of the host include bacteria, actinomycetes, yeast, fungi, plant cells, insect cells, and animal cells. Preferred hosts include microorganisms such as bacteria and yeast. More preferred hosts include bacteria. Examples of bacteria include gram negative bacteria and gram positive bacteria. Examples of Gram-negative bacteria include bacteria belonging to the family Enterobacteriaceae such as Escherichia bacteria, Enterobacter bacteria, Pantoea bacteria, and the like. Examples of Gram-positive bacteria include coryneform bacteria such as Bacillus bacteria and Corynebacterium bacteria. Examples of bacteria belonging to the genus Escherichia include Escherichia coli. Examples of coryneform bacteria include Corynebacterium glutamicum and Corynebacterium ammoniagenes (Corynebacterium stationis). Among them, Escherichia coli can be preferably used as the host. Specific examples of Escherichia coli include, for example, Escherichia coli K-12 strains such as W3110 strain (ATCC 27325) and MG1655 strain (ATCC 47076); Escherichia coli K5 strain (ATCC 23506); BL21 (DE3) strain And Escherichia coli B strains such as the BLR (DE3) strain, which is a recA-strain thereof, and derivatives thereof.

These strains can be sold, for example, from the American Type Culture Collection (address 12301 Parklawn Drive, Rockville, Maryland 20852 PO Box 1549, Manassas, VA 20108, United States of America). That is, a registration number corresponding to each strain is given, and it is possible to receive a sale using this registration number (see http://www.atcc.org/). The registration number corresponding to each strain is described in the catalog of American Type Culture Collection. The BL21 (DE3) strain is available, for example, from Life Technologies (product number C6000-03). The BLR (DE3) strain is available, for example, from Merck Millipore (product number 69053).

The gene encoding the protein of the present invention can be obtained, for example, by inserting a base sequence encoding a cell adhesion sequence into a fibroin-like protein gene. Fibroin-like protein genes can be obtained by cloning from organisms having fibroin-like protein genes such as spiders and silkworms. For cloning, nucleic acids such as genomic DNA and cDNA containing the same gene can be used. The obtained fibroin-like protein gene can be used as a base of the gene encoding the protein of the present invention as it is or after being appropriately modified. Modification of a gene such as insertion of a base sequence encoding a cell adhesion sequence can be performed by a known method. For example, a target mutation can be introduced into a target site of DNA by a site-specific mutation method. That is, the coding region of a gene can be altered, for example, by site-directed mutagenesis such that the amino acid residue at a particular site of the encoded protein includes substitutions, deletions, insertions, and / or additions. . As a site-specific mutation method, a method using PCR (Higuchi, R., 61, in PCR technology, Erlich, HA Eds., Stockton press (1989); Carter, P., Meth. In Enzymol., 154, 382 (1987)) and methods using phage (Kramer, W. and Frits, HJ, Meth. In Enzymol., 154, 350 (1987); Kunkel, TA et al., Meth. In Enzymol., 154, 367 ( 1987)). The gene encoding the protein of the present invention can also be obtained by, for example, chemical synthesis (Gene, 60 (1), 115-127 (1987)).

  The technique for introducing the gene encoding the protein of the present invention into the host is not particularly limited. In the host, the gene encoding the protein of the present invention may be retained so that it can be expressed under the control of a promoter that functions in the host. In the host, the gene encoding the protein of the present invention may be present on a vector autonomously replicating outside the chromosome, such as a plasmid, or may be introduced on the chromosome. The host may have only one copy of the gene encoding the protein of the present invention, or may have two or more copies. The host may have only one gene encoding the protein of the present invention, or may have genes encoding two or more types of the protein of the present invention.

The promoter for expressing the gene encoding the protein of the present invention is not particularly limited as long as it functions in the host. The “promoter that functions in the host” refers to a promoter having promoter activity in the host. The promoter may be a host-derived promoter or a heterologous promoter. The promoter may be a native promoter of a gene encoding the protein of the present invention, or may be a promoter of another gene. The promoter may be a stronger promoter than the native promoter of the gene encoding the protein of the present invention. Examples of strong promoters that function in Enterobacteriaceae bacteria such as Escherichia coli include, for example, T7 promoter, trp promoter, trc promoter, lac promoter, tac promoter, tet promoter, araBAD promoter, rpoH promoter, PR promoter, and PL promoter is mentioned. In addition, as a strong promoter that functions in coryneform bacteria, artificially modified P54-6 promoter (Appl. Microbiol. Biotechnolo., 53, 674-679 (2000)), acetic acid in coryneform bacteria, Pta, aceA, aceB, adh, amyE promoter that can be induced by ethanol, pyruvate, etc., cspB, SOD, tuf (EF-Tu) promoter (Journal of Biotechnology 104 ( 2003) 311-323, Appl Environ Microbiol. 2005 Dec; 71 (12): 8587-96.), Lac promoter, tac promoter, trc promoter. Moreover, as a promoter, you may acquire and utilize the highly active type of a conventional promoter by using various reporter genes. For example, the activity of the promoter can be increased by bringing the −35 and −10 regions in the promoter region closer to the consensus sequence (International Publication No. 00/18935). Highly active promoters include various tac-like promoters (Katashk
ina JI et al. Russian Federation Patent application 2006134574) and pnlp8 promoter (WO2010 / 027045). Methods for evaluating promoter strength and examples of strong promoters are described in Goldstein et al. (Prokaryotic promoters in biotechnology. Biotechnol. Annu. Rev., 1, 105-128 (1995)).

Further, a terminator for termination of transcription can be arranged downstream of the gene encoding the protein of the present invention. The terminator is not particularly limited as long as it functions in the host. The terminator may be a host-derived terminator or a heterologous terminator. The terminator may be a terminator specific to the gene encoding the protein of the present invention, or may be a terminator of another gene. Specific examples of the terminator include T7 terminator, T4 terminator, fd phage terminator, tet terminator, and trpA terminator.

The gene encoding the protein of the present invention can be introduced into a host using a vector containing the gene, for example. A vector containing a gene encoding the protein of the present invention is also referred to as an expression vector or a recombinant vector for the gene encoding the protein of the present invention. An expression vector for a gene encoding the protein of the present invention can be constructed, for example, by linking a DNA fragment containing the gene encoding the protein of the present invention to a vector that functions in the host. By transforming the host with the expression vector of the gene encoding the protein of the present invention, a transformant into which the vector has been introduced can be obtained, that is, the gene can be introduced into the host. As the vector, a vector capable of autonomous replication in a host cell can be used. The vector is preferably a multicopy vector. Further, the vector preferably has a marker such as an antibiotic resistance gene in order to select a transformant. Moreover, the vector may be equipped with a promoter or terminator for expressing the inserted gene. The vector may be, for example, a vector derived from a bacterial plasmid, a vector derived from a yeast plasmid, a vector derived from a bacteriophage, a cosmid, or a phagemid. Specific examples of vectors capable of autonomous replication in Enterobacteriaceae such as Escherichia coli include pUC19, pUC18, pHSG299, pHSG399, pHSG398, pBR322, and pSTV29 (all available from Takara Bio Inc.)
, PACYC184, pMW219 (Nippon Gene), pTrc99A (Pharmacia), pPROK vector (Clontech), pKK233-2 (Clontech), pET vector (Novagen), pQE vector (Qiagen), pACYC, A broad host range vector RSF1010 is mentioned. Specific examples of vectors capable of autonomous replication in coryneform bacteria include, for example, pHM1519 (Agric. Biol. Chem., 48, 2901-2903 (1984)); pAM330 (Agric. Biol. Chem., 48, 2901- 2903 (1984)); plasmids having improved drug resistance genes; plasmid pCRY30 described in JP-A-3-210184; plasmid pCRY21 described in JP-A-2-72876 and US Pat. No. 5,185,262. PCRY2KE, pCRY2KX, pCRY31, pCRY3KE and pCRY3KX; plasmids pCRY2 and pCRY3 described in JP-A-1-91686; pAJ655, pAJ611 and pAJ1844 described in JP-A-58-192900; JP-A-57-134500 Examples include pCG1 described in the publication; pCG2 described in JP-A-58-35197; pCG4 and pCG11 described in JP-A-57-183799. When constructing an expression vector, for example, a gene encoding the protein of the present invention containing a unique promoter region may be directly incorporated into the vector, and the coding region of the protein of the present invention is linked downstream of the promoter as described above. Then, it may be incorporated into the vector, or the coding region of the protein of the present invention may be incorporated downstream of the promoter inherent in the vector.

  Vectors, promoters, and terminators that can be used in various microorganisms are described in detail in, for example, “Basic Course of Microbiology 8 Genetic Engineering, Kyoritsu Shuppan, 1987”, and these can be used.

The gene encoding the protein of the present invention can be introduced, for example, onto the host chromosome. Introduction of a gene into a chromosome can be performed, for example, using homologous recombination (Miller, JH Experiments in Molecular Genetics, 1972, Cold Spring Harbor Laboratory). As a gene transfer method using homologous recombination, for example, the Red-driven integration method (Datsenko, KA, and Wanner, BL Proc. Natl. Acad. Sci. US A. 97: 6640-6645 (2000)), etc., a method using a linear DNA, a method using a plasmid containing a temperature-sensitive replication origin, a method using a plasmid capable of conjugation transfer, a method using a suicide vector that does not have a replication origin and functions in a host, A transduction method using a phage can be mentioned. Only one copy of the gene may be introduced, or two copies or more may be introduced. For example, multiple copies of a gene can be introduced into a chromosome by performing homologous recombination with a sequence having multiple copies on the chromosome as a target. Examples of sequences having multiple copies on a chromosome include repetitive DNA sequences and inverted repeats present at both ends of a transposon.
In addition, homologous recombination may be performed by targeting an appropriate sequence on a chromosome such as a gene unnecessary for carrying out the present invention. The gene can also be randomly introduced onto the chromosome using transposon or Mini-Mu (Japanese Patent Laid-Open No. 2-109985, US Pat. No. 5,882,888, EP805867B1). When the gene is introduced into the chromosome, for example, the gene encoding the protein of the present invention containing a unique promoter region may be directly incorporated into the chromosome, and the coding region of the protein of the present invention is downstream of the promoter as described above. May be incorporated into the chromosome after binding to the protein, or the coding region of the protein of the present invention may be incorporated downstream of the promoter originally present on the chromosome.

  The introduction of a gene onto a chromosome can be attributed to, for example, Southern hybridization using a probe having a base sequence complementary to all or part of the gene, or a primer prepared based on the base sequence of the gene. Can be confirmed by PCR.

The transformation method is not particularly limited, and a conventionally known method can be used. As a transformation method, for example, a method of increasing the permeability of DNA by treating a recipient cell with calcium chloride as reported for Escherichia coli K-12 (Mandel, M. and Higa, A., J. Mol.
Biol. 1970, 53, 159-162), as described for Bacillus subtilis, a method of preparing competent cells from proliferating cells and introducing DNA (Duncan, CH, Wilson, GA and Young, FE., 1997. Gene 1: 153-167). In addition, as a transformation method, recombinant DNA is prepared by transforming DNA-receptive cells, such as those known for Bacillus subtilis, actinomycetes, and yeast, into a protoplast or spheroplast state that easily incorporates recombinant DNA. (Chang, S. and Choen, SN, 1979. Mol. Gen. Genet. 168: 111-115; Bibb, MJ, Ward, JM and Hopwood, OA 1978. Nature 274: 398- 400; Hinnen, A., Hicks, JB and Fink, GR 1978. Proc. Natl. Acad. Sci. USA 75: 1929-1933). As a transformation method, an electric pulse method (Japanese Patent Laid-Open No. 2-207791) as reported for coryneform bacteria can also be used.

  By culturing a host having a gene encoding the protein of the present invention, the protein of the present invention can be expressed. At that time, gene expression is induced as necessary. Host culture conditions and gene expression induction conditions may be appropriately selected according to various conditions such as marker type, promoter type, and host type. The medium used for the culture is not particularly limited as long as the host can proliferate and can express the protein of the present invention. As the medium, for example, a normal medium containing a carbon source, a nitrogen source, a sulfur source, inorganic ions, and other organic components as required can be used.

  Examples of the carbon source include sugars such as glucose, fructose, sucrose, molasses, and starch hydrolysates, alcohols such as glycerol and ethanol, and organic acids such as fumaric acid, citric acid, and succinic acid.

  Examples of the nitrogen source include inorganic ammonium salts such as ammonium sulfate, ammonium chloride, and ammonium phosphate, organic nitrogen such as soybean hydrolysate, ammonia gas, and aqueous ammonia.

  Examples of the sulfur source include inorganic sulfur compounds such as sulfate, sulfite, sulfide, hyposulfite, and thiosulfate.

  Examples of inorganic ions include calcium ions, magnesium ions, manganese ions, potassium ions, iron ions, and phosphate ions.

  Other organic components include organic trace nutrient sources. Examples of organic micronutrients include required substances such as vitamin B1, yeast extract containing them, and the like.

  The culture temperature may be, for example, 20 ° C to 45 ° C, preferably 24 ° C to 45 ° C, more preferably 30 ° C to 37 ° C. The culture is preferably aeration culture. In this case, the oxygen concentration may be adjusted to, for example, 5 to 50%, preferably 20 to 40% with respect to the saturation concentration. The pH during the culture is preferably 5-9. In addition, inorganic or organic acidic or alkaline substances such as calcium carbonate, ammonia gas, aqueous ammonia, etc. can be used for pH adjustment. The culture time may be, for example, 10 hours to 120 hours.

In particular, when Escherichia coli is used as a host, organic acid accumulation during induction of expression of the protein of the present invention is reduced (WO2015 / 178465) and cell growth after induction of expression of the protein of the present invention is reduced ( WO2015 / 178466) is expected to be able to produce the protein of the present invention efficiently.

  By culturing a host having a gene encoding the protein of the present invention as described above, the protein of the present invention accumulates in the medium and / or in the cells. The protein of the present invention can accumulate, for example, as inclusion bodies in the microbial cells.

  The recovery and quantification of the protein of the present invention can be performed, for example, by a known method for recovering and quantifying a heterologously expressed protein (for example, “Neurochemistry Experiment Course, Protein VI Synthesis and Expression”, Japanese Biochemical Society, Tokyo Kagaku Dojin (1992). pp 183-184).

Hereinafter, the procedure for recovery and quantification in the case where the protein of the present invention accumulates as inclusion bodies in the cells will be exemplified. First, cells are collected from the culture solution by centrifugation and then suspended in a buffer solution. The bacterial cell suspension is subjected to treatment such as ultrasonic treatment and French press to crush the bacterial cells. Prior to cell disruption, lysozyme may be added to the cell suspension at a final concentration of 0-200 mg / l and left in ice for 30 minutes to 20 hours. The insoluble fraction is then obtained as a precipitate from the crushed material by low-speed centrifugation (6000-15000 rpm, 5-10 minutes, 4 ° C.). The insoluble fraction is appropriately washed with a buffer as necessary. The number of times of washing is not particularly limited, and may be, for example, once, twice, or three times or more. A suspension of the protein of the present invention is obtained by suspending the insoluble fraction with a buffer. As a buffer for suspending bacterial cells or the protein of the present invention, a buffer solution having low solubility of the protein of the present invention can be preferably used. Examples of such a buffer include a Tris-HCl buffer containing NaCl. The pH of the buffer solution may be, for example, usually 4 to 12, preferably 6 to 9. Further, the protein solution of the present invention can be obtained by dissolving the insoluble fraction with an SDS solution or a urea solution. The protein of the present invention to be recovered is other than the protein of the present invention,
Components such as bacterial cells, medium components, and bacterial metabolic byproducts may be included. The protein of the present invention may be purified to a desired degree. The protein of the present invention can be purified by a known method used for protein purification. Examples of such a method include ammonium sulfate fractionation, ion exchange chromatography, hydrophobic chromatography, affinity chromatography, gel filtration chromatography, isoelectric precipitation, and dialysis. One of these methods may be used alone, or two or more thereof may be used in appropriate combination. The amount of the protein of the present invention is determined by, for example, subjecting a sample containing the protein of the present invention such as a suspension or a solution to SDS-PAGE and staining, and the intensity of the band corresponding to the molecular weight of the target protein of the present invention. Can be determined based on Staining includes CBB staining, fluorescent staining,
It can be performed by silver staining or the like. In quantification, a protein with a known concentration can be used as a standard. Examples of such a protein include albumin and the protein of the present invention whose concentration has been separately determined.

  The use of the protein of the present invention is not particularly limited. The protein of the present invention may be used, for example, for medical use or research use. The protein of the present invention exhibits a scaffold function for cells such as stem cells. Therefore, the protein of the present invention may be used for culturing cells such as stem cells. Specifically, the protein of the present invention may be used, for example, as a scaffold protein for cell culture. Moreover, you may utilize the protein of this invention as a component of instruments, such as a cell culture instrument. Specifically, the protein of the present invention may be used by coating the surface of a device such as a cell culture container. About an instrument and cell culture, description about the instrument of this invention mentioned later and the method of this invention can apply mutatis mutandis.

<2> Composition of the present invention The composition of the present invention is a composition containing the protein of the present invention. The use of the composition of the present invention is not particularly limited. The composition of the present invention may be used, for example, for medical use or research use. That is, the composition of the present invention may be, for example, a medical or research composition. Specifically, the composition of the present invention may be used, for example, for culturing cells such as stem cells. That is, the composition of the present invention may specifically be a composition for cell culture, for example. More specifically, the composition of the present invention may be, for example, a cell scaffold material. “Cell scaffold material” refers to a structure that functions as a cell scaffold, and specifically refers to a structure that functions as a cell scaffold during cell culture. The cell scaffold material can be used for cell culture, for example. That is, cells can be cultured using a cell scaffold material as a scaffold. Cell culture results (cultured cells, cell sheets, tissues, organs, etc.) obtained using cell scaffold materials can be collected from, for example, cell scaffold materials or desired for treatment, etc. It can be used for Further, the cell scaffold material may be implanted into a living body and used for culturing cells in a living body (tissue formation through cell adhesion and proliferation, etc.). More specifically, the composition of the present invention may be a coating agent for an instrument such as a cell culture container. About an instrument and cell culture, description about the instrument of this invention mentioned later and the method of this invention can apply mutatis mutandis.

  The composition of the present invention may or may not consist of the protein of the present invention. The composition of the present invention may be a combination of the protein of the present invention and other components. That is, the protein of the present invention can be used as the composition of the present invention alone or in combination with other components. The other components are not particularly limited as long as they have acceptable properties according to the use mode of the composition of the present invention. Examples of other components include those used by blending with pharmaceuticals and reagents. Specific examples of such components include additives such as excipients, binders, disintegrants, lubricants, stabilizers, corrigents, flavoring agents, fragrances, diluents, and surfactants. Can be mentioned.

The concentration (content) of the protein of the present invention in the composition of the present invention is not particularly limited.
The concentration of the protein of the present invention in the composition of the present invention can be appropriately set according to various conditions such as the mode of use of the composition of the present invention. The concentration of the protein of the present invention in the composition of the present invention is, for example, 0.01% (w / w) or more, 0.1% (w / w) or more, 1% (w / w) or more, 5% ( w / w) or more, or 10% (w / w) or more, 100% (w / w) or less, 99.9% (w / w) or less, 70% (w / w) or less, 50% (w / w) or less, 30% (w / w) or less, 10% (w / w) or less, or 5% (w / w) or less, or 1% (w / w) or less Of course, they may be a consistent combination.

  The shape of the composition of the present invention is not particularly limited. The shape of the composition of this invention can be suitably set according to various conditions, such as the utilization aspect of the composition of this invention. The composition of the present invention may be formulated in a desired shape. Specifically, as the shape of the composition of the present invention, for example, liquid (solution or suspension, etc.), paste, powder, granule, sphere, tablet, foam, sponge, fiber, film, sheet, membrane, mesh Tube.

  The composition of the present invention may be used for a desired application (for example, coating of an instrument), for example, as it is, or appropriately diluted, dispersed, or dissolved in a medium such as water or an aqueous buffer. Needless to say, such dilution, dispersion, or dissolution is also included in the scope of the composition of the present invention.

<3> Instrument of the Present Invention The instrument of the present invention is an instrument comprising the protein of the present invention. The application of the instrument of the present invention is not particularly limited. The device of the present invention may be used, for example, for medical use or research use. That is, the device of the present invention may be, for example, a medical device or a research device. Specifically, the device of the present invention may be used, for example, for culturing cells such as stem cells. That is, the instrument of the present invention may specifically be a cell culture instrument, for example. Cell culture devices include cell culture containers and cell scaffold materials. The device of the present invention which is a cell culture container is also referred to as “the culture container of the present invention”. The device of the present invention which is a cell scaffold material is also particularly referred to as “cell scaffold material of the present invention”. The instrument of the present invention may be provided with the protein of the present invention in an embodiment in which the function of the protein of the present invention is exhibited. The device of the present invention may have, for example, the protein of the present invention on its surface. That is, the device of the present invention may specifically be, for example, a device whose surface is coated with the protein of the present invention. In addition, when the protein of the present invention or the composition of the present invention is configured in a form that can be used as a device as it is, the protein of the present invention or the composition of the present invention may be used as it is as the device of the present invention. . Specifically, for example, when the composition of the present invention is configured as a cell scaffold material, the composition of the present invention may be used as it is as the cell scaffold material of the present invention. For cell culture, the description of the method of the present invention described later can be applied mutatis mutandis.

  Hereinafter, although the instrument of the present invention will be described mainly with reference to the culture vessel, the description can be applied to other instruments. That is, the following description can be applied to other appliances as they are, or appropriately changed according to various conditions such as the aspect and use of the appliance.

The culture vessel is not particularly limited as long as it has a material and shape capable of culturing cells. The culture container may have, for example, a material and a shape that can hold cells and a culture medium. Specific examples of the shape of the culture vessel include a dish, a multiwell plate, a flask, a cell insert, and a membrane. Specific examples of the culture vessel material include polyethylene terephthalate (PET), polystyrene (PS), polycarbonate (PC), triacetyl cellulose (TAC), polyimide (PI), nylon (Ny), low density polyethylene ( LDPE), medium density polyethylene (MDPE), vinyl chloride, vinylidene chloride, polyphenylene sulfide, polyether sulfone, polyethylene naphthalate, polypropylene, urethane acrylate and other plastics, polylactic acid, polyglycolic acid, polycaprolactan, etc. And biodegradable polymers such as copolymers, glasses such as glass and modified glass, ceramics, metals, cellulose, and other various polymer compounds.

  The culture container of the present invention comprises the protein of the present invention at least on the cell culture surface. That is, for example, the cell culture surface of the culture container of the present invention may be coated with the protein of the present invention. The “cell culture surface” refers to a surface on which cell culture is performed, and specifically refers to a site that can come into contact with cells during cell culture. The protein of the present invention may or may not coat the entire cell culture surface of the culture container as long as cells such as stem cells can be cultured using the culture container of the present invention. The ratio of the area of the portion coated with the protein of the present invention to the total area of the cell culture surface of the culture vessel is, for example, 50% or more, 70% or more, 80% or more, 90% or more, or 95% or more. It's okay. In general, the protein of the present invention preferably coats the entire cell culture surface of the culture vessel. For example, if the culture vessel is in a dish shape, the entire bottom surface is preferably coated with the protein of the present invention.

  The technique for coating the cell culture surface of the culture vessel with the protein of the present invention is not particularly limited. Coating the cell culture surface of the culture vessel with the protein of the present invention can be carried out, for example, using a known technique for coating the surface of the culture vessel with a functional material. For example, the cell culture surface of the culture container can be coated with the protein of the present invention by applying a solution containing the protein of the present invention to the cell culture surface of the culture container. Specifically, for example, the cell culture surface of the culture container is coated with the protein of the present invention by applying a solution containing the protein of the present invention to the cell culture surface of the culture container and drying (vaporizing the solvent). be able to. More specifically, for example, when a time (hereinafter also referred to as “coating time”) elapses after the solution containing the protein of the present invention is applied to the cell culture surface of the culture vessel, cell culture in the culture vessel is performed. The surface can be coated with the protein of the invention. The coating time is not particularly limited as long as the cell culture surface of the culture vessel can be coated with the protein of the present invention to a desired degree. The coating time may be, for example, 30 minutes or more, 1 hour or more, 6 hours or more, 12 hours or more, or 18 hours or more, 72 hours or less, 48 hours or less, or 30 hours or less, A combination thereof may also be used. After the coating time has elapsed, the remaining solution can be removed as appropriate and can be dried. The culture container can be sterilized as appropriate. The culture container can be sterilized, for example, after the cell culture surface of the culture container is coated with the protein of the present invention. For sterilization, for example, alcohol such as ethanol or 2-propanol can be used. The alcohol may be used as a hydrous alcohol such as 70% ethanol. Sterilization can be performed, for example, by applying alcohol to the cell culture surface or immersing the culture container in alcohol. As described above, sterilization before cell culture can be performed using alcohol. However, in order to ensure completeness, the solution containing the protein of the present invention is sterilized by filter sterilization or the like and then applied to the cell culture surface of the culture vessel. The subsequent operations may be performed under aseptic conditions. For filter sterilization, for example, a filter such as Milex manufactured by Merck Millipore can be used. Aseptic operations can be performed as appropriate. The culture container of the present invention may be used immediately after production (after the coating of the protein of the present invention), or may be used after being properly stored. The culture container of the present invention is effective for culturing cells such as stem cells even when not used immediately after production. The storage temperature may be, for example, 0 ° C to 50 ° C, 0 ° C to 40 ° C, 0 ° C to 25 ° C, or 0 ° C to 10 ° C. The storage period may be, for example, 1 year or less, 6 months or less, or 1 month or less. The culture container of the present invention may be stored in a dry state or in a wet state. For example, the cell culture surface may be stored in a state wetted with a buffer solution such as PBS.

The coating amount of the protein of the present invention on the surface of the culture container is not particularly limited as long as cells such as stem cells can be cultured using the culture container of the present invention. Coating amount of the protein of the present invention to the culture vessel surface is, for example, 0.1 [mu] g / cm ² or more, 0.2 [mu] g / cm ² or more, 0.4 [mu] g / cm ² or more, 1 [mu] g / cm ² or more, or 5 [mu] g / cm ² or more, 500 μg / cm ² or less, 250 μg / cm ² or less, 100 μg / cm ² or less, or 5
It may be 0 μg / cm ² or less, or a combination thereof. Specifically, the coating amount of the protein of the present invention on the surface of the culture container is, for example, 0.1 μg / cm ^2.
~500μg / cm ^2, preferably from ^{0.2μg / cm 2 ~250μg / cm 2} , more preferably may be ^{0.4μg / cm 2 ~100μg / cm 2} .

  Similarly, the cell scaffold material of the present invention can be appropriately obtained. The cell scaffold material is not particularly limited as long as it has a material and shape capable of culturing cells. The cell scaffold material may have, for example, a shape corresponding to the shape of a target cell culture result (cell sheet, tissue, organ, etc.). The cell scaffold material may be configured, for example, in a form having voids such as porous so that cells are filled in the cell scaffold material. The material of the cell scaffold material is preferably a bioabsorbable polymer from the viewpoint of being suitable for implantation in a living body, for example. Specific examples of bioabsorbable polymers include polylactic acid, polyglycolic acid, copolymers of lactic acid and glycolic acid, polycaprolactone, collagen, gelatin, glycosaminoglycan, chitin, chitosan, hyaluronic acid, poly Peptides are mentioned. The cell scaffold material of the present invention can be obtained, for example, by coating the surface of the cell scaffold material (specifically, the cell culture surface) with the protein of the present invention. It should be noted that the “surface of the cell scaffold material” includes the surface inside the void when the cell scaffold material is configured in a form having voids. For example, as described above, the composition of the present invention configured as a cell scaffold material may be used as it is as the cell scaffold material of the present invention.

<4> Method of the Present Invention Cells such as stem cells can be efficiently cultured using the protein of the present invention. Specifically, cells such as stem cells can be efficiently cultured using a device (the device of the present invention) provided with the protein of the present invention. More specifically, cells such as stem cells can be efficiently cultured using a culture instrument comprising the protein of the present invention, such as the culture container of the present invention or the cell scaffold material of the present invention. That is, this invention provides the method of culture | cultivating a cell including culturing a cell with the instrument of this invention, such as the culture container of this invention, and the cell scaffold material of this invention. This method is also referred to as “the method of the present invention”. The protein of the present invention is particularly effective for the proliferation of stem cells such as iPS cells. That is, the protein of the present invention and a cell culture instrument such as a cell culture container or a cell scaffold material provided with the protein can be used, for example, for growing stem cells such as iPS cells. In addition, the protein of the present invention and cell culture devices such as cell culture containers and cell scaffold materials provided with the protein are not limited to the proliferation of stem cells such as iPS cells. For example, the establishment of stem cells such as iPS cells in the previous stage In addition, it can also be used for differentiation of stem cells such as iPS cells in the subsequent stage. That is, in the present invention, “culture of cells” is not limited to cell proliferation, but includes, for example, establishment of cells having differentiation ability such as stem cells and progenitor cells, and other cells having differentiation ability such as stem cells and precursor cells. Is also included. Specifically, “culture of stem cells” is not limited to the proliferation of stem cells. For example, establishment of stem cells (for example, establishment of universal stem cells such as iPS cells and ES cells or pluripotent stem cells) and differentiation of stem cells (For example, differentiation from stem cells such as iPS cells and ES cells into other stem cells, progenitor cells, or mature cells) is also included. By the method of the present invention, cultured cells (cultured cells) can be obtained. That is, one aspect of the method of the present invention is a method for producing cultured cells, comprising culturing cells with the device of the present invention such as the culture container of the present invention and the cell scaffold material of the present invention. The cultured cells obtained by the method of the present invention may or may not be differentiated. That is, the cultured cells obtained by the method of the present invention may be maintained in an undifferentiated state or may have acquired an undifferentiated state, for example. The cultured cells obtained by the method of the present invention may be, for example, cells having differentiation ability such as stem cells and progenitor cells, or may be differentiated cells such as progenitor cells and mature cells. The cultured cells obtained by the method of the present invention may be, for example, free cells (individual independent cells) or organized cells such as cell sheets, tissues, organs and the like.

The type of cells to be cultured is not particularly limited. The method of the present invention can be suitably used particularly for stem cell culture. Specific examples of stem cells include embryonic stem cells (ES cells), induced pluripotent stem cells (iPS cells), pluripotent germ stem cells (mGS cells), neural stem cells, mesenchymal stem cells, and hematopoietic stem cells. It is done. More specifically, examples of the stem cells include embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells). The cell may be derived from any living tissue. Examples of biological tissues include skin, cornea, liver, digestive organs, mammary gland, prostate, hair root, trachea, and oral mucosa. The organism from which the cells are derived is not particularly limited and can be appropriately selected according to the purpose of use. Examples of organisms from which cells are derived include mammals. Specific examples of mammals include human, rat, mouse, guinea pig, marmoset, rabbit, dog, cat, sheep, pig and chimpanzee. The mammal may be an immunodeficient animal. When cultured cells are used for human therapy, the organism from which the cells are derived is preferably, for example, a mammal selected from humans, pigs, and chimpanzees. In the method of the present invention, only one type of cell may be cultured, or two or more types of cells may be co-cultured.

The culture conditions are not particularly limited as long as desired culture results (cell proliferation, stem cell establishment, cell differentiation, etc.) can be obtained. The culture conditions are the same as, for example, normal conditions used for culturing cells such as ES cells and iPS cells, except that the device of the present invention such as the culture container of the present invention and the cell scaffold material of the present invention is used. It's okay. The culture conditions can be appropriately set according to various conditions such as the aspect of the device of the present invention, the type of cells, the biological species from which the cells are derived.

The composition of the medium can be appropriately set according to various conditions such as the properties of cells to be cultured. Examples of the medium components include carbon sources such as glucose, amino acids, vitamins, phosphates, buffers, growth factors, serum, and serum albumin. Specific examples of the normal medium used for cell culture include α-MEM, DMEM, and KCM. Further, as a normal medium used for culturing embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells), specifically, for example, Essential 8 medium (manufactured by Invitrogen), StemFit (R) medium (Made by Ajinomoto Co., Inc.) and other media used in the examples.

  According to the method of the present invention, cells such as stem cells can be efficiently cultured without using feeder cells or other cell adhesion proteins (cell adhesion proteins other than the protein of the present invention). However, this does not preclude the use of feeder cells or other cell adhesion proteins. That is, in the method of the present invention, feeder cells and other cell adhesion proteins (cell adhesion proteins other than the protein of the present invention) may or may not be used. In the method of the present invention, it is preferable to reduce the amount of feeder cells and other cell adhesion proteins used compared to the usual amount used for cell culture. In the method of the present invention, it is more preferable not to use feeder cells or other cell adhesion proteins.

The number of cells to be seeded at the start of the culture may be, for example, 1 × 10 ³ cells / cm ² or more, 1 × 10 ⁴ cells / cm ² or more, or 2 × 10 ⁴ cells / cm ² or more, and 1 × 10 ⁶ cells / cm ² or less, 1 × 10 ⁵ cells / cm ² or less, or 5 × 10 ⁴ ce
lls / cm ² or less or a combination thereof. The culture temperature is
For example, it may be 36 ° C to 38 ° C, preferably about 37 ° C. The culture pH may be, for example, pH 6.8 to 7.2. The gas phase at the time of culture may be, for example, a mixed gas of air and carbon dioxide. Specifically, for example, the culture may be performed in an atmosphere of 5% carbon dioxide gas and 95% air. The culture period may be, for example, 5 to 30 days, preferably 7 to 16 days. During the culture, the medium may be changed.

  By performing cell culture in this manner, cultured cells are obtained.

  Hereinafter, the present invention will be described more specifically based on examples.

Example 1: Preparation of laminin partial sequence insertion fibroin-like protein <1> Construction of laminin partial sequence insertion fibroin-like protein expression strain Plasmid pET22b-ADF3 expressing a gene encoding fibroin-like protein ADF3
Was constructed by cleaving the pET22b (+) vector (Novagen) with restriction enzymes NdeI and EcoRI, and then inserting the fully synthesized fibroin-like protein gene ADF3 using DNA Ligation Kit (TaKaRa). The base sequence of the ADF3 gene is shown in SEQ ID NO: 1, and the amino acid sequence of the fibroin-like protein ADF3 encoded by the same gene is shown in SEQ ID NO: 2. The ADF3 protein shown in SEQ ID NO: 2 has a His tag and an HRV3C protease recognition sequence at the N-terminus.

The plasmid pET22b-ADF3Laminin # 39, which expresses the gene encoding the laminin partial sequence insertion fibroin-like protein ADF3Laminin # 39, is a fibroin-like protein that is fully synthesized after cleaving the pET22b (+) vector (Novagen) with restriction enzymes NdeI and EcoRI. The gene ADF3Laminin # 39 was constructed using the DNA Ligation Kit (TaKaRa). The base sequence of the ADF3Laminin # 39 gene is shown in SEQ ID NO: 3, and the amino acid sequence of the fibroin-like protein ADF3Laminin # 39 encoded by the same gene is shown in SEQ ID NO: 4. ADF3Laminin # 39 is composed of one laminin partial sequence “RGLDATARKASRRS” (SEQ ID NO: 40) inserted into 7 of 10 ADF non-rich sites of ADF3 protein shown in SEQ ID NO: 2 (7 in total). is there.

Similarly, laminin partial sequence insertion fibroin-like protein ADF3Laminin # 34, ADF3Laminin # 37, ADF3Laminin # 38, ADF3Laminin # 42, ADF3Laminin # 43, ADF3Laminin # 44, ADF3Laminin # 45, ADF3Laminin # 46, ADF3Laminin # 47, and ADF3Laminin # 47 The genes encoding each of these are fully synthesized and introduced into the pET22b (+) vector, and plasmids pET22b-ADF3Laminin # 34, pET22b-ADF3Laminin # 37, pET22b-ADF3Laminin # 38, pET22b-ADF3Laminin # 42 that express these genes , PET22b-ADF3Laminin # 43, pET22b-ADF3Laminin # 44, pET22b-ADF3Laminin # 45, pET22b-ADF3Laminin # 46, pET22b-ADF3Laminin # 47, and pET22b-ADF3Laminin # 48 were constructed. The nucleotide sequences of these genes are shown in SEQ ID NOs: 51 to 60, and the amino acid sequences of fibroin-like proteins encoded by the genes are shown in SEQ ID NOs: 61 to 70. These fibroin-like proteins are composed of 7 laminin partial sequences SIYITRF (SEQ ID NO: 44), NVFVQRL (SEQ ID NO: 38), VAFYSN (SEQ ID NO: 38) in 10 of the 10 ADF non-rich sites of ADF3 protein shown in SEQ ID NO: 2, respectively. SEQ ID NO: 37), LLNLRPDDFVFYVGG (SEQ ID NO: 34), LKRLNTTGV (SEQ ID NO: 36), VFDLQQNLGSV (SEQ ID NO: 39), LNEEVVSLYNF (SEQ ID NO: 35), DIARAEMLLEEAKRA (SEQ ID NO: 41), KLQLLKDLE (SEQ ID NO: 42), ALGSAAADA (sequence) Number 43) is inserted one by one (a total of seven).

ADF3Laminin # 39 may be abbreviated as “ADF3 # 39”. The same applies to other laminin partial sequence insertion fibroin-like proteins.

PET22b-ADF3, pET22b-ADF3Laminin # 39, pET22b-ADF3Laminin # 34, pET22b-ADF3Laminin # 37, pET22b-ADF3Laminin # 38, pET22b-ADF3Laminin # 42, pET22b-ADF3Laminin # 43, AET3Laminin # 43, pET22b-ADF3 Escherichia coli BL21 (DE3) ΔrecA for # 45, pET22b-ADF3Laminin # 46, pET22b-ADF3Laminin # 47, and pET22b-ADF3Laminin # 48, respectively
By transforming the strain, fibroin-like protein producing bacteria BL21 (DE3) ΔrecA / pET22b
-ADF3, BL21 (DE3) ΔrecA / pET22b-ADF3Laminin # 39, BL21 (DE3) ΔrecA / pET22b-ADF3Laminin # 34, BL21 (DE3) ΔrecA / pET22b-ADF3Laminin # 37, BL21 (DE3) ΔrecA / pET22b-ADF3Lainin # 39 , BL21 (DE3) ΔrecA / pET22b-ADF3Laminin # 42, BL21 (DE3) ΔrecA / pET22b-ADF3Laminin # 43
, BL21 (DE3) ΔrecA / pET22b-ADF3Laminin # 44, BL21 (DE3) ΔrecA / pET22b-ADF3Laminin # 45, BL21 (DE3) ΔrecA / pET22b-ADF3Laminin # 46, BL21 (DE3) ΔrecA / pET22b-ADF3Laminin # 44 BL21 (DE3) ΔrecA / pET22b-ADF3Laminin # 48 was obtained. BL21 (DE3) ΔrecA strain is BL21 (DE3)
It is obtained by deleting the recA gene from the strain by the λRed method.

<2> Expression of laminin partial sequence inserted fibroin-like protein Fibroin-like protein expression strain BL21 (DE3) ΔrecA / pET22b-ADF3, BL21 obtained above
ΔrecA / pET22b-ADF3Laminin # 39, BL21 (DE3) ΔrecA / pET22b-ADF3Laminin # 34, BL21 (DE3) ΔrecA / pET22b-ADF3Laminin # 37, BL21 (DE3) ΔrecA / pET22b-ADF3Laminin # 38, BL21 (DE3) A21 pET22b-ADF3Laminin # 42, BL21 (DE3) ΔrecA / pET22b-ADF3Laminin # 43, BL21 (DE3) ΔrecA / pET22b-ADF3Laminin # 44, BL21 (DE3) ΔrecA / pET22b-ADF3Laminin # 45, BL21 (DE3) ΔrecA / p22 ADF3Laminin # 46, BL21 (DE3) ΔrecA / pET22b-ADF3Laminin # 47, and BL21 (DE3) ΔrecA / pET22b-ADF3Laminin # 48 were used at 1 vvm, 37 ° C, 1500 rpm, pH 6. Culturing was carried out under the conditions of 7 until all the glucose was consumed to obtain a seed culture solution. Thereafter, 45 mL of the seed culture solution was added to 255 mL of the production medium shown in (2), and main culture was performed under conditions of 1 vvm, 37 ° C., 700 rpm, and pH 6.9. After 30 minutes of culture, the feed medium shown in (3) was added at a flow rate of 2.6 mL / h, and the culture was cultured until the OD value at 620 nm reached 50. Thereafter, the culture temperature was lowered to 30 ° C., and 1 mM isopropyl-β-thiogalactopyranoside (IPTG) was added to induce protein expression. The culture was terminated 24 hours after the addition of IPTG to obtain a culture solution. When a cell disruption solution was prepared and subjected to SDS-PAGE, a band of the desired size was observed, confirming that fibroin-like protein was expressed in the cell.

(1) Seed medium glucose 40 g / L, magnesium sulfate heptahydrate 1.0 g / L, corn steep liquor 1.0 g / L (
Nitrogen weight conversion), potassium dihydrogen phosphate 2.0g / L, iron sulfate heptahydrate 10mg / L, manganese sulfate heptahydrate 10mg / L, GD-113 (antifoaming agent) 0.1ml / L, ampicillin 100mg / L

(2) Production medium glucose 2.5 g / L, magnesium sulfate heptahydrate 2.4 g / L, corn steep liquor 1.0 g / L (nitrogen weight conversion), potassium dihydrogen phosphate 5.4 g / L, iron sulfate heptahydrate 40mg / L, manganese sulfate heptahydrate 40mg / L, calcium chloride dihydrate 40mg / L, GD-113 (antifoam) 0.1ml / L, ampicillin 100mg / L

(3) Feed medium glucose 700g / L, ampicillin 100mg / L

<3> Purification of laminin partial sequence-inserted fibroin-like protein The culture solution obtained above was diluted with the Lysis buffer shown in (1) so that the OD value was 30, and sonicated. The treatment solution was centrifuged and only the precipitate was collected. To the precipitate, an equal volume of 3% SDS solution was added to the pre-centrifugation treatment solution, and suspended for 30 min with a homogenizer. The suspension was centrifuged and only the precipitate was collected again. The solubilization buffer shown in (2) was added to the precipitate so that the target protein concentration was 5 mg / ml and suspended by vortexing. The suspension was centrifuged and only the supernatant was collected.

  The resulting supernatant was dialyzed with a 500-1000 Da dialysis membrane using NaOH solution (pH 10) as the external solution, and fibroin-like proteins ADF3, ADF3Laminin # 39, ADF3Laminin # 34, ADF3Laminin # 37, ADF3Laminin # 38, ADF3Laminin # 42, ADF3Laminin # 43, ADF3Laminin # 44, ADF3Laminin # 45, ADF3Laminin # 46, ADF3Laminin # 47, and ADF3Laminin # 48 were obtained.

(1) Lysis buffer
30 mM Tris-HCl, 100 mM NaCl, pH 7.5

(2) Solubilization buffer
50 mM NaOH

Example 2 Evaluation of Cell Scaffold Function of Fibroin-like Protein <1> Coating on Cell Culture Plate An aqueous solution of fibroin-like protein obtained after dialysis obtained in Example 1 <3> above was added to a 6-well cell culture plate (Corning Falcon). 1 to 4 ml / well was added to the culture plate) and left at room temperature for one day or two nights to volatilize water. The cell culture plate was immersed in a 70% aqueous ethanol solution and then washed with phosphate buffered saline (Nacalai Tesque).

<2> Confirmation of coating FT-IR total reflection measurement (FT-IR-ATR) of the coating surface was performed using Shimadzu IR Prestige-21 and Smiths Dura Sampl IR II, an ATR measuring device. . In the obtained spectrum, the peak derived from the protein main chain amide group (α amide bond) appeared in the range of 1620-1700 cm ⁻¹ , confirming that the fibroin-like protein was coated on the cell culture plate. . The coating amount of fibroin-like protein is considered to be about 10 μg / cm ² .

<3> Evaluation in iPS cell proliferation system The adhesion proliferation effect of artificial pluripotent stem cells (iPS cells) on the surface coated with fibroin-like protein was evaluated. The 201B7 strain purchased from iPS Portal was used as the iPS cell. Cell culture is a medium obtained by adding human serum albumin (final concentration 2.6 mg / ml, Sigma-Aldrich) to Essential 8 medium (manufactured by Invitrogen), which is a medium for iPS cells, or StemFit (R) medium (Ajinomoto Co., Inc.). Ltd.) was used to perform under the conditions of 5% CO _2/37 ℃. The effect was examined by coating a fibroin-like protein on a cell culture plate and using it immediately in culture. A single cell was seeded with 100,000 live cells per well. Y-27632 was added to the medium (final concentration 10 μM, manufactured by Nacalai Tesque), and the medium was changed every 2 to 4 days. After culturing for 6 to 7 days, the number of cells detached by treatment with a cell dissociating enzyme (Life Technologies TrypLE Select) was measured using a cell number measuring device (Beckman Coulter ViCell).

  The results are shown in FIG. 1 and FIG.

As shown in FIG. 1, all fibroin-like proteins into which a laminin partial sequence has been inserted have a viable cell count of 2 to 11 times that after seeding and have a good iPS cell scaffolding function. (That is, these laminin partial sequences have properties as cell adhesion sequences).

Moreover, when ADF3, a fibroin-like protein into which no partial sequence of laminin was inserted, was evaluated by the same method, almost no seeded cells adhered, and there were no viable cell counts 6 days after seeding. (Not shown). This indicates that the iPS cell scaffold function is expressed by inserting a partial sequence of laminin.

In addition, pronectin (Sanyo Kasei Kogyo), a silkworm fibroin inserted with a cell adhesion sequence containing RGD of fibronectin, a scaffold protein, was evaluated by the same method. As in ADF3, 6 days after seeding, There were no numbers (not shown). This indicates that the present invention is difficult to predict.

  As shown in FIG. 2, ADF3 # 39, a fibroin-like protein into which a laminin partial sequence was inserted, could be cultured for 2 weeks by one passage in the middle. After culturing for 2 weeks, staining was performed using an alkaline phosphatase staining kit (Sigma Aldrich: 86-R). As a result, it was confirmed that the undifferentiated state of the cells was maintained. This indicates that by utilizing the product of the present invention, it is possible to proliferate while maintaining the undifferentiated state of iPS cells in long-term culture.

Example 3 Evaluation of Cell Adhesion Inhibiting Function of Various Peptides <1> Preparation of Various Peptides Various peptides were prepared by an ordinary solid phase synthesis method at a peptide synthesis commissioned organization.

<2> Evaluation of iPS Cell Adhesion Inhibitory Function The artificial pluripotent stem cell (iPS cell) adhesion inhibitory function of various peptides was evaluated. The 201B7 strain purchased from iPS Portal was used as the iPS cell. Cell culture is a medium obtained by adding human serum albumin (final concentration 2.6 mg / ml, Sigma-Aldrich) to Essential 8 medium (manufactured by Invitrogen), which is a medium for iPS cells, or StemFit (R) medium (Ajinomoto Co., Inc.). Made)
Was used to carried out under the conditions of 5% CO _2/37 ℃. After suspending iPS cells for 5 minutes to 2 hours in a medium containing various amounts of various peptides, coat cell scaffolds such as iMatrix (Nippi) or Matrigel (Nippon Becton Dickinson) according to the method of the product protocol. The cell culture plate was seeded with a single cell so that the number of viable cells per well was 13,000 to 40,000.
Y-27632 (final concentration 10 μM, manufactured by Nacalai Tesque) is added to the medium.
And it culture | cultivated in the culture medium which did not add any peptide. The culture medium is changed every 1 to 3 days, and after culturing for 5 to 7 days, the number of cells detached by treatment with cell dissociation enzyme TrypLE Select (Life Technologies) is measured using ViCell (Beckman Coulter) Measured.

  3 and 4, iPS cells were suspended in a medium containing 0-100 μM of RKRLQVQLSIRT (SEQ ID NO: 47), which is a partial peptide of mouse laminin α1, and then iMatrix (FIG. 3) or Matrigel (FIG. 4). 5 shows the results of culturing for 5 days after seeding a single cell so that the number of viable cells per well is 13,000 (FIG. 3) or 40,000 (FIG. 4) on a cell culture plate coated with. Since RKRLQVQLSIRT showed the effect of inhibiting cell adhesion growth on cell culture plates coated with any cell scaffold, fibroin-like protein inserted with RKRLQVQLSIRT may have a good iPS cell scaffold function. I can expect.

  In FIG. 5, iPS cells were suspended in a medium containing 0-100 μM of GCISNVFVQRLL (SEQ ID NO: 72), a partial peptide of human laminin α5, and then viable cells per well were coated on a cell culture plate coated with iMatrix. The results of single cell seeding so that the number is 13,000 and culturing for 5 days are shown.

  In FIG. 6, iPS cells are suspended in a medium containing 0-100 μM of AASIKVAVSADR (SEQ ID NO: 73), which is a partial peptide of human laminin α1, and then viable cells per well are coated on a cell culture plate coated with iMatrix. The results of single cell seeding so that the number is 13,000 and culturing for 5 days are shown.

FIG. 7 includes 0-100 μM of PGASIKVAVSAGPS (SEQ ID NO: 74), which is a peptide consisting of an amino acid sequence obtained by modifying a partial sequence of human laminin α1, and which is also a partial sequence peptide such as Pronectin L described in JP-A 2010-220611 The result of suspending iPS cells in a medium and then seeding them on a cell culture plate coated with iMatrix so that the number of viable cells per well is 13,000 and culturing for 5 days is shown.

  Since these peptides also showed an effect of inhibiting cell adhesion proliferation, it can be expected that fibroin-like proteins inserted with these peptides have a good iPS cell scaffold function.

<Explanation of Sequence Listing>
SEQ ID NO: 1: Fibroin-like protein gene ADF3 base sequence SEQ ID NO: 2: Fibroin-like protein ADF3 amino acid sequence SEQ ID NO: 3: Laminin partial sequence insertion fibroin-like protein gene ADF3 Laminin # 39 base sequence SEQ ID NO: 4: Laminin partial sequence insertion fibroin Amino acid sequence of the like protein ADF3Laminin # 39 SEQ ID NO: 5: amino acid sequence of human laminin α3 chain SEQ ID NO: 6: amino acid sequence of human laminin α5 chain SEQ ID NO: 7-10: amino acid sequence SEQ ID NO: 11-21 of the portion satisfying the requirements of Ala-rich site : Amino acid sequence of a motif contained in a portion satisfying the requirements of Ala non-rich site SEQ ID NO: 22: Amino acid sequence of human laminin β1 chain SEQ ID NO: 23: Amino acid sequence of human laminin β2 chain SEQ ID NO: 24: Amino acid sequence of human laminin β3 chain SEQ ID NO: 25 : Hitomi Amino acid sequence of nin γ1 chain SEQ ID NO: 26: Amino acid sequence of human laminin γ2 chain SEQ ID NO: 27: Amino acid sequence of mouse laminin α1 chain SEQ ID NO: 28: Amino acid sequence of mouse laminin α2 chain SEQ ID NO: 29: Amino acid sequence of mouse laminin α3 chain No. 30: amino acid sequence of mouse laminin α5 chain SEQ ID NO: 31 amino acid sequence of mouse laminin β1 chain SEQ ID NO: 32 amino acid sequence of mouse laminin β3 chain SEQ ID NO: 33: amino acid sequence of human vitronectin SEQ ID NOs: 34 to 50: RGD included No amino acid sequence of cell adhesion sequence SEQ ID NO: 51: base sequence of laminin partial sequence inserted fibroin-like protein gene ADF3Laminin # 34 52: base sequence of laminin partial sequence inserted fibroin-like protein gene ADF3Laminin # 37 SEQ ID NO: 53: laminin partial sequence Insertion fee Loin-like protein gene ADF3Laminin # 38 nucleotide sequence SEQ ID NO: 54: Laminin partial sequence inserted fibroin-like protein gene ADF3Laminin # 42 nucleotide sequence SEQ ID NO: 55: Laminin partial sequence-inserted fibroin-like protein gene ADF3Laminin # 43 nucleotide sequence SEQ ID NO: 56: Laminin partial sequence insertion fibroin-like protein gene ADF3Laminin # 44 nucleotide sequence SEQ ID NO: 57: Laminin partial sequence insertion fibroin-like protein gene ADF3Laminin # 45 nucleotide sequence SEQ ID NO: 58: Laminin partial sequence insertion fibroin-like protein gene ADF3Laminin # 46 SEQ ID NO: 59: Laminin partial sequence insertion fibroin-like protein gene ADF3Laminin # 47 base sequence SEQ ID NO: 60: Laminin partial sequence insertion fibroin-like protein gene ADF3 Laminin # 48 base sequence SEQ ID NO: 61: Laminin partial sequence insertion fibre Amino acid sequence of loin-like protein ADF3Laminin # 34 SEQ ID NO: 62: amino acid sequence of laminin partial sequence insertion fibroin-like protein ADF3Laminin # 37 63: amino acid sequence of laminin partial sequence insertion fibroin-like protein ADF3Laminin # 38 SEQ ID NO: 64: laminin partial sequence Amino acid sequence of the inserted fibroin-like protein ADF3Laminin # 42 SEQ ID NO: 65: Amino acid sequence of the inserted fibroin-like protein ADF3Laminin # 43 SEQ ID NO: 66: Amino acid sequence of the inserted fibroin-like protein ADF3Laminin # 44 SEQ ID NO: 67: Laminin portion Amino acid sequence of sequence insertion fibroin-like protein ADF3Laminin # 45 SEQ ID NO: 68: Amino acid sequence of fibroin-like protein insertion ADF3 Laminin # 46 SEQ ID NO: 69: Fibroin-like tamper insertion of laminin partial sequence Quality ADF3Laminin # 47 amino acid sequence SEQ ID NO 70: laminin partial sequence inserted fibroin-like protein ADF3Laminin # 48 amino acid sequence SEQ ID NO: 71: human laminin α1 chain amino acid sequence SEQ ID NO 72 to 74: the amino acid sequence of the cell adhesion sequence without the RGD

Claims (39)

A protein comprising a repetitive structure and a cell adhesion sequence,
The repeating structure consists of 3 to 15 repetitions of the repeating unit,
Each repeating unit is formed by connecting an Ala-rich part and an Ala-non-rich part,
Each Ala-rich site consists of an amino acid sequence of 8 to 54 residues,
The ratio of Ala residues in each Ala-rich site is 30% or more,
Each Ala-rich site contains at least one Ala residue in any four consecutive amino acid residues in the same site;
Each non-Ala-rich site consists of an amino acid sequence of 4 residues or more,
The ratio of Ala residues in each Ala non-rich site is 20% or less,
The cell adhesion sequence is contained in one or more repeating units selected from repeating units constituting the repeating structure;
A protein in which each cell adhesion sequence is a partial amino acid sequence of a cell adhesion protein and comprises an amino acid sequence of 5 or more residues that does not contain Arg-Gly-Asp.   The protein according to claim 1, wherein the cell adhesion sequence is contained in two or more repeating units selected from repeating units constituting the repeating structure.   The protein according to claim 1 or 2, wherein the total number of the cell adhesion sequences contained in the protein is 1 to 50.   The protein according to any one of claims 1 to 3, wherein each cell adhesion sequence is inserted in an Ala non-rich site or a connecting portion between an Ala-rich site and an Ala non-rich site.   The protein according to any one of claims 1 to 4, wherein the cell adhesion protein is laminin or vitronectin. The protein according to any one of claims 1 to 5, wherein each cell adhesion sequence consists of the amino acid sequence described in (a), (b), or (c) below:
(A) amino acid sequence represented by amino acid numbers 2113 to 2124 of SEQ ID NO: 71; amino acid numbers 2866 to 2880, 2905 to 2915, 3102 to 3111, 3204 to 3209, 3260 to 3270, 3264 to 3270, 3264 to 3286 of SEQ ID NO: 6 , Or the amino acid sequence shown in 3306-3319; the amino acid sequence shown in amino acid number 1567-1581 of SEQ ID NO: 22, or the amino acid sequence shown in amino acid number 1411-1419 of SEQ ID NO: 25; ˜2216, 2397 to 2402, 2742 to 2753, or 2745 to 2752; the amino acid sequence shown to amino acid numbers 367 to 377 of SEQ ID NO: 33; the starting position of these amino acid numbers and / or Or a combination of their amino acid sequence; amino acid sequence completion position is one behind 1-5 residues;
(B) an amino acid sequence comprising 1 to 3 amino acid residue substitutions, deletions, insertions, and / or additions in the amino acid sequence shown in (a), and does not contain Arg-Gly-Asp; (c) An amino acid sequence having 80% or more identity to the amino acid sequence shown in (a) and not containing Arg-Gly-Asp. The protein according to any one of claims 1 to 6, wherein each cell adhesion sequence consists of the amino acid sequence described in the following (a), (b), or (c):
(A) the amino acid sequence shown in any one of SEQ ID NOs: 34 to 44, 47, 49, 50, and 72 to 74;
(B) including substitution, deletion, insertion, and / or addition of 1 to 3 amino acid residues in the amino acid sequence shown in any of SEQ ID NOs: 34 to 44, 47, 49, 50, and 72 to 74, And an amino acid sequence not containing Arg-Gly-Asp;
(C) an amino acid sequence having 80% or more identity to the amino acid sequence shown in any of SEQ ID NOs: 34 to 44, 47, 49, 50, and 72 to 74 and not containing Arg-Gly-Asp .   The protein according to any one of claims 1 to 7, wherein each cell adhesion sequence is composed of an amino acid sequence having a function of inhibiting adhesion of an induced pluripotent stem cell to a cell scaffold.   The protein according to any one of claims 1 to 8, wherein each Ala-rich site consists of an amino acid sequence of 8 to 15 residues.   The protein according to any one of claims 1 to 9, wherein each Ala-rich site consists of an amino acid sequence of 9 residues.   The protein according to any one of claims 1 to 10, wherein each Ala-rich site contains one or more Gly residues and Ser residues, respectively.   The protein according to any one of claims 1 to 11, wherein a ratio of Ala residues in each Ala-rich site is 50% or more.   The protein according to any one of claims 1 to 12, wherein the ratio of Ala residue, Gly residue, and Ser residue in each Ala-rich site is 90% or more in total. The protein according to any one of claims 1 to 13, wherein each Ala-rich site consists of the amino acid sequence described in (a), (b), or (c) below:
(A) the amino acid sequence shown in SEQ ID NO: 7, 8, 9, or 10;
(B) an amino acid sequence comprising substitution, deletion, insertion, and / or addition of 1 to 3 amino acid residues in the amino acid sequence shown in SEQ ID NO: 7, 8, 9, or 10;
(C) an amino acid sequence having 80% or more identity to the amino acid sequence shown in SEQ ID NO: 7, 8, 9, or 10.   The protein according to any one of claims 1 to 14, wherein each Ala non-rich site consists of an amino acid sequence of 15 to 100 residues.   The protein according to any one of claims 1 to 15, wherein a ratio of Ala residues in each Ala non-rich site is 5% or less.   The ratio of Gly residue, Ser residue, Gln residue, Pro residue, and Tyr residue in each Ala non-rich site is 90% or more in total, 17. Protein. 18. Each Ala non-rich site includes one or more amino acid sequences selected from the amino acid sequences set forth in (a), (b), and (c) below: Proteins described in:
(A) the amino acid sequence shown in SEQ ID NOs: 11 to 21;
(B) an amino acid sequence comprising substitution, deletion, insertion and / or addition of 1 to 3 amino acid residues in the amino acid sequence shown in SEQ ID NOs: 11 to 21;
(C) An amino acid sequence having 80% or more identity to the amino acid sequences shown in SEQ ID NOs: 11 to 21. The protein according to any one of claims 1 to 18, wherein each Ala non-rich site consists of an amino acid sequence described in (a), (b), or (c) below:
(A) amino acid numbers 62-91, 101-120, 130-151, 161-185, 195-218, 228-257, 267-291, 301-325, 335-369, 379-438, 448 of SEQ ID NO: 2. The amino acid sequence shown in ~ 497 or 507-536;
(B) amino acid numbers 62-91, 101-120, 130-151, 161-185, 195-218, 228-257, 267-291, 301-325, 335-369, 379-438, 448 of SEQ ID NO: 2. An amino acid sequence comprising substitutions, deletions, insertions and / or additions of 1 to 10 amino acid residues in the amino acid sequence shown in ˜497 or 507 to 536;
(C) amino acid numbers 62-91, 101-120, 130-151, 161-185, 195-218, 228-257, 267-291, 301-325, 335-369, 379-438, 448 of SEQ ID NO: 2. An amino acid sequence having 90% or more identity to the amino acid sequence shown in ˜497 or 507 to 536.   The composition containing the protein of any one of Claims 1-19.   21. The composition of claim 20, which is a cell scaffold material.   The composition according to claim 21, wherein the cell scaffold material is for stem cell culture.   The composition according to claim 22, wherein the stem cells are embryonic stem cells or induced pluripotent stem cells.   The composition according to claim 20, which is a coating agent for cell culture containers.   The composition according to claim 24, wherein the cell culture container is for culturing stem cells.   26. The composition according to claim 25, wherein the stem cell is an embryonic stem cell or an induced pluripotent stem cell.   An instrument comprising the protein of any one of claims 1-19.   28. A device according to claim 27 which is a medical or research device.   29. A device according to claim 27 or 28 which is a cell culture vessel.   29. A device according to claim 27 or 28 which is a cell scaffold material.   30. The device of claim 29, wherein a cell culture surface is coated with the protein.   The instrument according to any one of claims 27 to 31, which is used for culturing stem cells.   33. The device of claim 32, wherein the stem cell is an embryonic stem cell or an induced pluripotent stem cell.   A method for producing a cultured cell, comprising culturing a cell with the device according to any one of claims 27 to 33.   35. The method of claim 34, wherein the cultured cells are stem cells.   36. The method of claim 35, wherein the stem cell is an embryonic stem cell or an induced pluripotent stem cell.   The gene which codes the protein of any one of Claims 1-19.   A vector carrying the gene according to claim 37.   A host comprising the gene according to claim 37.